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Abstract 
 With the expansion of both health insurance coverage and the scale of health 
insurance fund, the basic Chinese health insurance has covered 97% of the Chinese 
population. As a result, the payment from third parties accounts for a large amount of 
healthcare expense. These result in increasing power from the third party payers to 
influence the healthcare market and the delivery of care in the long run. Thus, using 
advanced information technology to improve administrative ability and developing 
analytical methods for health insurance data to aid managerial decisions and policy 
implementation are needed. Risk adjustment of health insurance represents an 
opportunity to improve efficiency and equity of the health system. This study is the first 
time to validate and evaluate one of the best known risk adjustment methods - the Johns 
Hopkins Adjusted Clinical Groups (ACG) Case-Mix System to China's health system 
based on large amounts of Chinese health insurance claims.  
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1 INTRODUCTION 
1.1 Background 
1.1.1 Chinese Healthcare System 
The People’s Republic of China has a population of over 1.3 billion people, 
representing about 19% of the world’s population. With a land mass of approximately 9.6 
million square kilometers over 33 provinces and a population density of 139.6 per square 
kilometers, China is the most populous country, the second largest country by land and 
the second largest economy in the world.
1,2
 Over the past 20 years, as the Chinese 
economy has expanded, the annual total health expenditure, which is the sum of both 
public and private spending on health goods and services, has increased significantly 
(Figure 1.1).
3
 The total health expenditure constantly accounted for 3%-4% of its GDP 
since the economic reform started in the 1980s and it represented about 5% of the 
Chinese GDP in the past decade. With the ongoing healthcare reform, the percentage of 
the GDP of the total health expenditures from the public sector has increased, and the 
percentage of the GDP of the total health expenditures from the private sector has 
deceased (Figure 1.2).
3
 However, as a nation with the largest population, the health 
expenditure per capita still remains low relative to developed countries (Figure 1.3)
3
.  
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Figure 1.1 Total Health Expenditure of China by Years 
 
Figure 1.2 Public, Private and Total Health Expenditures in Percentages of GDP 
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Figure 1.3 Health Expenditure per Capita 
 
 Along with the significant increase in health expenditures, healthcare has become 
a leading national concern as seeking care is expensive for Chinese citizens. According to 
the Third National Health Service Survey from the Ministry of Health,
4
 in 2003,  the 
average cost of a single hospital admission was 4,123 Chinese Yuan, which accounted for 
nearly 50% of the average annual income, 8,472 Yuan, of a Chinese citizen of that year.  
Furthermore, more than 70% of the country’s population did not have any health 
insurance during that time. Therefore, large portions of the populations were exposed to 
financial risks because of the high out-of-pocket healthcare cost. To solve this problem, 
the government advanced the existing basic public health insurance system by developing 
new insurance plans for different populations and increasing the overall reimbursement 
level of public health insurance programs. Initially, in the 1990s, the Urban Employee 
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(NCMS) was created for rural residents. Then, in 2007, the Urban Resident Basic 
Medical Insurance (URBMI) program was created for unemployed urban residents, 
particularly children and senior citizens. Recently, the Urban-Rural Medical Assistance 
System was also created for residents with financial difficulties.
5 
These four public 
insurance programs are the major components of the basic health insurance system which 
finances the basic medical care in China from the public sector.   
Through many years of healthcare reform and support from state and local 
governments, these public insurance programs have expanded significantly across the 
nation. As a result, the coverage ratio of health insurance increased significantly 
nationwide as shown in Figure 1.4.
6
 Besides the four basic public health insurance 
programs, there are also supplementary programs from the government with specific 
enrollment requirements. These programs are financed by special funds with different 
premium levels. Commercial health insurance programs, which cover advanced medical 
services, also serve as a supplementary part of the health insurance system.   
As the costs of healthcare has inflated significantly in the past ten years, a health 
system, without sufficient and effective health insurance programs supported by the 
government, may significantly widen the gap between the rich and poor for access to 
healthcare and cause considerable financial burdens on individuals and families. In April 
2009, the central government of China initiated a new healthcare reform program to 
improve the Chinese healthcare system. The objective of the reform was to provide 
Chinese citizens comprehensive access to healthcare by building a basic healthcare 
system that would cover all urban and rural residents by 2020. The comprehensive health 
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system includes the public health service system, the medical service system, the health 
insurance system, and the pharmacy supply system.
7
 Overall, the foundation of this 
comprehensive health system is the public health insurance system as it provides the 
major source to finance the healthcare. One characteristic of the public health insurance 
program is that it provides high coverage among populations; however, it has a relatively 
low to medium reimbursement rate with a certain stop loss, which is the maximum 
reimbursement amount of the healthcare expenses from an insurance program. In 
summary, the new health insurance system provides the groundwork to achieve one of 
the important goals of the healthcare reform by creating national health insurance to 
cover basic health needs for the entire population of China. 
Figure 1.4 Health Insurance Coverage in China 
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health benefits from the public insurance programs are different among provinces due to 
the different levels of financial support from local governments. The commercial sector 
currently only covers a small percentage of the general population because only 
international companies or large state owned companies may sponsor health insurance 
from commercial sectors as additional benefits to their employees. Individuals with a 
significant high income may also purchase commercial health insurance for oneself or 
one’s family to mitigate the financial risk from unexpected high medical expenses.  
However, some commercial companies may offer service to the government to manage 
the public health insurance claims as a third-party administrator (TPA). With the ongoing 
health reform, China has changed its health system toward a universal and 
comprehensive health insurance system. The four public basic health insurance programs, 
together with various supplementary programs from commercial sectors cover 
populations with different demands of healthcare service.   
As payments for healthcare related expenses from third party payers have 
accounted for a significant amount of the total healthcare expenditure nationally, a large 
number of health insurance claims have been generated on a daily basis. The 
infrastructure of information technologies (IT) is essential to facilitate claim submission, 
data collection and care management. In recent years, the implementation of electronic 
health records (EHR), which is supported by the government, has promoted the 
widespread usage of IT systems in the Chinese health system. Most large Chinese 
hospitals, which have the financial capacity and needs, have implemented EHRs and 
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other hospital management information systems for documentation, management and 
payment transaction purposes.
5,8
    
Due to the electronic collection of health insurance claims and the expanded 
coverage of health insurance among different populations, developing data-driven 
methods for analysis and management of health insurance is feasible. These advanced 
methods will significantly benefit healthcare administrations for achieving an efficient 
and equitable healthcare finance system, in which the inflation of healthcare cost can be 
controlled while the quality of care can be insured.   
1.1.2 Disease Burden 
The primary factor in determining healthcare utilization is the pattern of disease 
burden within a population.
9
 In order to determine the disease burden, it is necessary to 
have a valid method to measure the morbidity and comorbidity in a population and study 
their patterns within a population. Comorbidity means that different diseases occur in a 
patient at the same time. It also represents challenges to healthcare management because 
traditional healthcare management and analysis focused only on individual diseases. In 
addition, as medicine evolves, new medications, medical devices, and treatments have 
contributed to the survival rate in populations. Therefore, comorbidity, which usually 
increases progressively with age, is a feature in all populations, and this feature has a 
significant impact on healthcare costs and utilization rates.
9
  
Understanding the disease burden is essential for experts in policy making, health 
services research, and healthcare management to provide a solution for improving the 
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efficiency and effectiveness of care. For research, it is important to understand the 
patterns of both the healthcare needs and the delivery of care among populations. For 
healthcare policy makers and managers, it is important to know if the allocation of 
healthcare resources is matched with the disease burden for the population. Moreover, 
organizations providing healthcare services should be equitably reimbursed for the 
disease burden of the population that they serve. Therefore, for stakeholders in 
governments and healthcare organizations, a valid method to measure disease burdens in 
populations is important because quantifying the differences in morbidities among 
populations is the necessary component for analytic applications in payment adjustment, 
health insurance risk assessment, and provider evaluation.
10,11
   
1.1.3 Risk Adjustment of Health Insurance  
Risk can be characterized by two factors:  the probability of an event to happen 
and the loss from an event.
12
 In healthcare, the loss can be financial for healthcare cost 
analysis or functional for clinical outcome analysis. Risk adjustment of health insurance 
is to normalize the health risk of populations for risk assessment or analysis, which are 
based on the characteristics of the population, such as demographic and diagnostic 
information.
13
 Normalization means adjusting the data from different scales into a similar 
scale. Normalization of health risk is a process to convert various clinical conditions and 
risk factors into a unified scale of measurements in terms of the expected consumptions 
of healthcare resources. Risk adjustment methods have been widely applied in the 
domain of financial analysis, care management, performance assessment and population 
profiling in healthcare.
14,15,16,17,18
 For analysis, normalized populations are important 
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because the analytical process usually involves comparing groups or populations in 
different levels of health status or various risk profiles. Comparison requires equivalent 
populations for obtaining an unbiased result. Various risk profiles generated from 
different diagnosis of a patient in a population can be a confounding factor for analysis.  
In statistics, a confounding factor is a hidden variable that correlates with both the 
dependent variable and independent variable. Risk adjustment is one method to eliminate 
the confounding factor and reduce the clinical differences of study populations for further 
analysis.  
Risk adjustment of health insurance is one method to quantify the expected 
healthcare resource consumptions based on the health status of a population, or an 
individual. Traditional risk adjustment methods use demographic information, age and 
sex, for describing and adjusting a population’s health status and needs for healthcare 
services. However, these methods explain less than 10% of the variation of healthcare 
utilizations and costs.
19
 Therefore, in order to improve the efficiency and effectiveness of 
planning and allocating healthcare resources, a more effective method to analyze a 
population’s healthcare utilization pattern is necessary. Diagnostic information is 
commonly used for describing morbidities, assessing health risk and analyzing healthcare 
resource utilization in a population.
20,21,22,23,24
 As diagnostic information provides more 
detailed characteristics on the health of the population than the demographic information, 
risk adjustment models based on diagnostic information should be more effective. 
However, large numbers of diagnostic categories limit the direct usage of diagnostic 
information in statistical models for management purposes when analyzing a general 
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population because it is computationally expensive and the results are difficult to 
communicate and interpret. More sophisticated risk adjustment methods and instruments 
leveraging the power of an information system, which uses both demographic and 
clinical information to generate the disease burden of a population, can explain more than 
50% of the healthcare utilization and costs in a population of a retrospective analysis. It 
can be also used to predict more than 20% of the variation of utilization and costs of a  
prospective analysis.
19 
The explained variances from the analyses have significant 
implications for healthcare administration, policy and health service research. Therefore, 
using advanced analytical instruments and technologies to conduct risk adjustment can 
improve the study and the prediction of utilization and costs in healthcare. If the 
information can be used to support better decision making, then a health system that is 
comprehensive, universal, and equitable can be achieved.   
In the United States, the development of risk adjustment tools, used to adjust 
health risk based on the measurement of morbidity in populations, is designed to solve 
the problem of ‘risk segmentation’ between public and private insured populations for 
healthcare service.
25,26
 Health insurers and health plans apply risk adjustment tools to 
adjust financial data in a way that reflects the health status of members. For health 
outcomes research, a valid risk adjustment instrument can be used to adjust for systematic 
differences in illness burden among populations and reduce bias in comparison of the 
study outcome. In addition, risk adjustment tools offer a new view of studying what 
factors affect the resource utilization or health outcomes rather than a method that is 
based on the distribution of specific diseases from the view of public health.   
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The healthcare payment system for a national health system is essentially based 
on equitable re-distribution of healthcare resources while the payment system for a health 
system driven by the insurance market is based on risk selection.
9,18,27
 One of the 
important goals for a healthcare payment system is to maintain equity and pursue 
efficiency at the same time. A valid risk adjustment mechanism based on disease burdens 
among populations to adjust healthcare payment is widely believed to achieve this goal in 
either of the healthcare payment systems.
28
 Therefore, risk adjustment instruments are 
useful in different types of health systems.  
1.1.4 Predictive Modeling  
Predictive modeling is a statistical model which makes a statement about the 
future. Predictive modeling can be used in predictive analytics where data mining 
techniques are applied to make a prediction about future probabilities and trends of the 
studied variables. In healthcare, it is usually used to predict future healthcare costs based 
on the current patients’ data. When all patients’ data are aggregated, the cost of a 
population can be estimated. In addition, by comparing the estimated cost of an 
individual and the estimated cost of a population, a healthcare administrator can 
potentially identify the future high cost user within a population. In order to develop an 
effective predictive modeling for a population, the first necessary step is to apply risk 
adjustment to assess and adjust the health risk of the studied population. In other words, 
predictive modeling is an application based on the result of risk adjustment.
13
 Research 
has shown that a small percentage of the people in a population consumed a large 
proportion of healthcare resources.
29
 For example, in the United States, the high-cost 
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users, which were about 20% of the population, accounted for 80% of the healthcare 
expenditures.
15,30
 Therefore, identifying those high-cost users among populations for 
various management programs is one of the foremost strategies to control the escalating 
healthcare cost.
19,31
 Through management programs, early intervention can be delivered 
to these patients effectively at the early stage of the disease to help them manage their 
health conditions at a low cost.
32
 In the long run, this intervention can manage the cost of 
healthcare to keep it in a stable range.
31, 33
 Although predictive modeling has 
demonstrated the usefulness for better healthcare management in many cases, previous 
research studies on predictive modeling were based on regional data from western 
countries.    
1.1.5 ACG System  
The Adjusted Clinical Groups (ACG) Case-Mix System was originally developed 
by the Bloomberg School of Public Health at Johns Hopkins University in 1991. Today, 
the ACG System is an industry standard risk adjustment and predictive modeling 
software. The latest version of the ACG system, is a computer-based algorithm that 
assesses the health status of people enrolled in a given health plan or health system. The 
ACG system provides simple, statistically valid and clinically relevant measures of risk 
or demand for healthcare resources and interventions. The ACG system uses the 
diagnosis-based case-mix risk adjustment methodology to classify patients. The ACG 
system offers a family of tools that focus on assessing the health risk and associated 
resource utilization for a given population. These tools include case-mix risk adjustment, 
morbidity classification, and predictive modeling. The ACG system provides an 
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individual profile of the entire population, including both the healthy and high risk people, 
which distinguishes from other risk adjustment systems.
10 
When individual profiles are 
aggregated, the health risk profile of a population can be generated.  
The ACG system was originally created for analyzing primary care service in 
United States. Over the past 20 years, it expanded internationally for both public and 
private healthcare delivery systems to help promote equitable, effective and efficient 
healthcare. Currently the ACG system is the most widely used population based case-mix 
risk adjustment system. The ACG system has been adopted by more than 200 healthcare 
organizations within the United States as well as globally to help to finance and manage 
the care of millions of people. It is currently used by 16 state Medicaid agencies in the 
United States as well as by 14 countries internationally. Since 2003, the ACG system, 
initially created from health insurance claim data in the United States, has been validated 
and adopted within numerous health systems globally, such as in Europe, North and 
South America, Middle East, and Africa. In addition, a large number of pilot and 
academic projects related to the ACG system are currently being studied in Europe, Asia, 
and Latin America. Internationally, ACG system has an active footprint in almost every 
continent.
10 
Previous research studies in those countries have demonstrated the ACG 
system has a statistically significant ability to account for the variance of healthcare 
service (outpatient, inpatient) expenditures across years.
34,35,36
 The ACG system has been 
used in capitation payment rate adjustment,
37,38
 prediction of healthcare utilization,
20,32 
physicians profiling
39,40,41,42
 and health service research
10,43 ,44
 internationally in the past.  
The section, international experiences on the ACG system, will discuss these related 
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studies in detail. The overall functionality of the ACG system is summarized in Figure 
1.5. 
Figure 1.5 Overview of the ACG System 
 
Source: The Johns Hopkins Adjusted Clinical Groups® (ACG®) System 
 
Although the ACG system has been validated extensively internationally, the 
experience with the system in China does not exist. In the current stage, the 
administrative data in the Chinese healthcare system has the potential to support using 
ACG system because the required input data to use the ACG system has been routinely 
collected in the Chinese healthcare system. Specifically, in the information system of 
large hospitals, the diagnostic codes supplied for reimbursement and management 
purposes, are based on International Classification of Diseases (ICD) version 10 with 
Chinese customization and the charges of a patient have recorded electronically. If a 
patient has health insurance, the hospital charge data will be sent either electronically 
from the hospital to the health insurance agency, or the patient will bring the related 
charge documents to health insurance agency to file a claim. Therefore, the data on 
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healthcare expenditures is available in various formats from both public and commercial 
health insurance organizations. The data on healthcare expenditures includes the total 
healthcare expense, the medication expense, reimbursement amount from health 
insurance, and payment from the patient including co-payment, deductible amount and 
self payment. Self payment means that the medical service or medication is not covered 
by the health insurance program.  
Based on demographic information (age and sex) and diagnostic information 
(ICD code) the ACG system eventually classifies each patient into one of the mutually 
exclusive categories, called ACG. Each category is derived from disease burden and 
represents a certain amount of demand for healthcare resources. The whole classification 
process of the ACG system contains two stages. First, the system assigns all ICD codes 
(version 9 or 10) into 32 diagnostic clusters, known as the Aggregated Diagnosis Groups 
(ADG), according to five clinical criteria: duration, severity, diagnostic certainly, 
etiology and specialty care. All diagnostic codes or all diseases can be classified into one 
of these 32 ADG categories.
10 
Because each patient may have multiple diagnoses in a 
population across time, each patient may be marked with multiple ADGs. Second, by 
using a branching algorithm, the ACG system places each patient into one of the 
mutually exclusive ACG categories, which is based on the combination of ADG, the 
demographic information and the healthcare cost of that patient. Patients within in the 
same ACG group are expected to have similar needs of healthcare resource utilization. A 
general illustration of the mapping and classification process mentioned above is shown 
in Figure 1.6. 
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Figure 1.6. ACG System Classification Flow 
 
Source: The Johns Hopkins Adjusted Clinical Groups® (ACG®) System10 
One of the essential methods used by the ACG system for classification is the 
decision tree branching algorithm as shown partially in Figure 1.7. A patient can be 
classified into one of the 105 ACG categories depending on the diagnostic and 
demographic information. If a patient is categorized with an acute major condition, one 
type of the ACG categories, the ACG branching process will end. In other words, 
reaching any of the ACG specific groups or acute major conditions represents the 
termination of the ACG grouping.
34
 After obtaining a final ACG group, the classification 
result can be used for further analyses, such as assessing the resource utilization, building 
regression models, or to explain the variation of healthcare costs among populations.  
The strength of the ACG system is that the development of its system is based 
both on commercial and public health insurance populations, which closely reflects the 
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health status of a general population and expands validity of the system across different 
health systems and nations. By contrast, other risk adjustment methods were developed 
using sick or disease specific patient populations such as the elderly population, poor or 
disabled patients from the publicly insured programs, or patients who have already been 
hospitalized.   
Figure 1.7 ACG System Decision Tree 
 
Source: Weiner et al 1991.  
1.1.6 International Experience on ACG System 
In the literature, the studies related to the ACG system have been reported from 
numerous countries and regions including the United States, Sweden, Spain, Canada, 
Australia, the United Kingdom, Italy, South Africa, Germany, Thailand, Taiwan, and 
Hong Kong. Particularly, during literature reviews, we have found that in Spain, Sweden, 
Canada, Taiwan and the United States, longitudinal or cross-section studies have been 
conducted in depth to answer various research questions in healthcare management.  
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Spain 
In Spain, starting in 1999, the research of the ACG system mainly focused on 
validating the ACG system in primary care settings to explain utilization by the risk 
adjustment method.
 
Studies on primary care costs were also reported. However, the cost 
for each patient level was based on an analytical accounting method. Contingent on the 
dependent variables, the studies reported that the risk adjustment method from the ACG 
system could explain about 40%-60% of the variations in primary care utilizations, and 
about 30%-40% of the variations of primary care costs.
 
The risk adjustment method 
based on age and gender explained about 10% of the variations of utilization, which was 
slightly higher compared to similar studies in other countries.
 
The data sets were either 
from the existing EHR systems using ICD-9-CM codes of the participating primary care 
providers or specifically collected for the research purpose.
45, 46,47 
The studies conducted 
earlier were based on small data sets that contained less than 10,000 patients from several 
locations. The most recent study was based on more than 300,000 people for healthcare 
cost analysis.
48
 
From those studies, the ACG system demonstrated useful analytical ability in a 
national health system and the classification results from the ACG system, which were 
assessed by the explained variance from the risk adjustment model, were consistent with 
the studies from United States. However, due to a lack of administrative databases, the 
validation and implementation process took a very long time to collect and assess data 
from various locations in Spain.  
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Taiwan 
In Taiwan, starting in 2008, the primary research on the risk adjustment method 
from the ACG system has focused on analyzing the national health insurance to explain 
the variations of total healthcare costs and ambulatory care utilizations from a morbidity 
perspective.
 
Lee and Huang first assessed the performance of the ACG system on 
utilizations and expenditures from a five-year longitudinal claims analysis of health 
insurance. The results of the diagnosis based risk adjustment, superior to the demographic 
model, were comparable to other countries and showed consistent performances across 
years. The data set consisted of about 190,000 people. The researchers found about 40%-
58% of the variations of utilizations and expenditures from the outpatient population 
could be explained by the ACG system. However, the ACG system did not explain the 
variations for the inpatient expenditures very well due to the system was originally 
developed based on outpatient populations.
28
 
In 2008, Lee qualitatively concluded the validity of the ACG system in Taiwan 
for quantifying the morbidities and the associated costs and utilizations for ambulatory 
care at the whole region level, based on a significantly large population of three million 
people. This study confirmed the consistency and reliability of the analytical ability of the 
ACG system on the whole healthcare system in Taiwan.
49
   
In 2010, Chang and Weiner reported an in-depth assessment on the performance 
of the ACG system in concurrent and prospective analyses of health insurance claims in 
Taiwan based on a data set of more than 1,600,000 people.
50
 They reported by using the 
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raw data, the total expenditures, which was the sum of the inpatient and outpatient 
expenditures, could be explained by the ACG system for about 15%-17% concurrently 
and about 8%-10% prospectively. For the models without outliers or the users of top 0.5% 
of costs, similar to the studies in other settings, the ACG system performed well and 
explained the variance of various healthcare expenditures, ranging from 20%-60% for 
different sets of data.  
Canada 
In 1999, Reid et al. first demonstrated the validity of the ACG system for 
measuring morbidities and explaining the variations of the care received by individuals 
and populations in Manitoba. They also developed an ACG morbidity index for the 
Canadian population.
25
 In 2001, Reid et al. measured the workload derived from the 
disease burdens of physician practices and studied the variations of morbidities across 
populations in Manitoba.
51
 Later, in 2002 Reid et al. assessed the validity of the ACG 
system to quantify the overall health service needs of populations based on the ACG 
morbidity index derived from the morbidity measured from the ACG system using health 
insurance claims.
52
    
In 2001, Reid et al. first systematically assessed the explanatory ability of the 
ACG system on healthcare costs in the Canadian healthcare system by using a large data 
set from two provinces. With similar results to the United States, they reported the ACG 
system was able to account for up to 50% and 40% of the truncated physician and total 
costs respectively from a concurrent analysis. From a prospective analysis, the system 
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explained up to 25% and 14% for these respective costs. The inpatient costs were 
estimated because no cost data was available at transaction level under the global 
payment method.
35
 
Sweden  
The research of the ACG system in Sweden was primarily focused on using it to 
explain utilizations in the Swedish healthcare system. In 1993, Carlsoon first assessed the 
feasibility to use the ACG system for allocating resources in primary healthcare based on 
a small dataset.
53
 In 2002, Carlsoon et al. reported the ACG system was a useful tool to 
describe population illness burdens based on a dataset from primary healthcare providers 
that managed a population of more than 10,000 people in one municipality.
54
 In 2004, 
using the ACG system, Carlsson et al. reported the distribution of morbidities and types 
of patients in a large population.
55
 In 2006, Carlsson et al. compared the variations of 
ACG distributions in Sweden from a three years data set and concluded the ACG 
distribution was fairly stable over time.
56
 However, the results from the last two studies 
conducted by Carlsson were still based on small data sets.  
Apart from evaluating the morbidity in the Swedish population, in 2006, 
Engström et al. first demonstrated the value of the risk adjustment system for explaining 
and predicting costs of patients in the Swedish primary care based on morbidities. They 
reported that the ACG weights could explain about 37.7% of the same year variation of 
the costs and predicted 14.3% of the costs for the next year based on a population of 
about 15,000 people for each year with a coding system in ICD-10.
57
 In 2009, Zielinski, 
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et al. conducted a large cross-sectional study to assess the ability of the ACG system for 
explaining and predicting the individual cost of primary care for the general population in 
Sweden. They concluded that using a more aggregated morbidity category, the Resource 
Utilization Bands (RUB) from the ACG system, the model was able to explain up to 63% 
of the variation of the costs.
58  
  
1.2 Significance  
Risk adjustment of health insurance represents an opportunity to improve the 
efficiency and equity of a healthcare system based on international experiences.  
Applications based on risk adjustment methods also provide solutions to various 
problems in healthcare management, such as utilization analysis, physician profiling, and 
cost containment. However, most valid risk adjustment models were originally developed 
from insurance claims data in western countries and the experiences of these models in 
Asia are limited. Furthermore, the concept of risk adjustment of health insurance is fairly 
novel in the Chinese healthcare system, and currently no risk adjustment method that is 
based on disease burdens has been systematically developed or validated in the Chinese 
Healthcare system. Thus, the proposed study will be the first time in history to validate a 
well-known diagnosis based risk adjustment method and evaluate its performance in the 
Chinese healthcare system. Knowledge from this study could provide novel 
recommendations on healthcare finance and solve problems encountered in the Chinese 
healthcare reform. Potentially, it would significantly improve the efficiency, equity and 
quality of healthcare in China. 
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Although the well-known ACG system has its footprints on almost every 
continent internationally and the research interests of the ACG system have been 
expressed from both China and the United States, for various reasons and difficulties, no 
studies have been conducted on the feasibility of the ACG system in the Chinese 
healthcare system. Therefore, this study will be the first time that the ACG system applies 
to China and demonstrates the value of risk adjustment results on Chinese health 
insurance. The primary difficulty is the acquisition of data, because in China, the 
secondary usage of healthcare insurance data between organizations, similar to 
international experiences, is very sensitive. Obtaining a few patients’ information would 
be possible. However, the validation of a risk adjustment instrument requires a great 
amount of data across many years. Thus, the scale of the secondary data usage makes the 
process of data acquisition more difficult. Furthermore, the proposed project involves 
using data outside of China, resulting in more difficult barriers and challenging conflicts 
for acquiring data on a large scale from different organizations.  
Due to the mentioned difficulties in obtaining related healthcare costs data in 
China, in the literature reviews, only a few studies are available regarding the healthcare 
costs or health insurance in China. Furthermore, most results from those infrequent 
studies are generated from publicly available, aggregated data from statistics or censuses.  
Studies based on data at transactional level are rare due to the availability of the data in 
the public, as well as the methods and instruments for analyzing complex healthcare costs 
data at large scale. Thus, the proposed project will be the first robust study that is based 
on a large amount of cross-sectional, concrete, and detailed transactional level data over 
 24 
 
several years to report the analytical results on healthcare costs. These results could also 
provide insights on the Chinese healthcare policy, the current stage of the healthcare 
reform, and the dynamic stages of the Chinese healthcare system. In addition, because the 
ACG system has been implemented in various organizations internationally, this 
proposed study will provide a unique opportunity for international comparison on 
healthcare costs and disease burdens, which have never been reported in the literature 
before.   
1.3 Research Questions and Hypothesis  
This study incorporates aspects of health service research, healthcare financing, 
statistics modeling, data mining, and health informatics. The primary research question 
for this study is: to what degree can the ACG system demonstrate the validity of the risk 
adjustment method to the Chinese healthcare system for explaining the variation of 
healthcare costs and what are the implications from the risk adjustment? Under the 
primary research questions, two sub-research questions can be asked: 1) what are the 
feasibility and utility of the risk adjustment methods from the ACG system to the Chinese 
healthcare system? 2) What are the distributions of the disease burdens from the process 
of risk adjustment and the relationships between the diseases burdens and the associated 
costs?   
This research project hypothesizes that in comparison with traditional 
demographic risk adjustment method, the western developed diagnosis based risk 
adjustment method is valid and more useful, to analyze health insurance data from the 
Chinese healthcare system with respect of explaining the variation of healthcare costs.   
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1.4 Study Aims 
The ultimate goal of this study is to provide recommendations on the Chinese 
healthcare financing methods from the risk adjustment perspective to enhance the 
efficacy, equity and quality of the health system. We propose to address this research 
question and to achieve the ultimate goal through the following specific aims sequentially 
by employing the ACG system as an instrument for the risk adjustment method.    
Aim 1: Assess the feasibility of the diagnosis based risk adjustment method from the ACG 
system to the Chinese health insurance data.  
Aim 2: Analyze the disease burdens and morbidity patterns derived from the ACG system 
of the patient populations of the insurance companies and the hospitals.  
Aim 3:  Evaluate the performance of the risk adjustment method from the ACG system on 
the explanatory ability of the healthcare costs for data from different regions and sources 
(hospital or insurance company) in the Chinese healthcare system and conclude the 
utility of the risk adjustment method to China. In addition, interpret the parameters and 
results from the risk adjustment models and compare healthcare expenditures with the 
similar studies internationally. Finally, provide recommendations on implementation of 
the risk adjustment method and explore applications from the results of the risk 
adjustment method.  
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2 METHODS 
2.1  Overview 
A set of qualitative and quantitative experiments utilizing the risk adjustment 
instrument-the ACG system and statistical analyses were conducted to test the hypothesis 
and to achieve the aims of this study. Our preliminary study, based on a very small data 
sample from a commercial insurance company in China, had demonstrated that the 
diagnosis based risk adjustment method derived from the ACG system could potentially 
support the data from the Chinese healthcare system.
59
 In this study, using the ACG 
system as an instrument, we aimed to assess the feasibility, study the disease burden and 
evaluate the performance of the risk adjustment method to the Chinese healthcare system 
based on significantly a large study population, which consisted of different types of data 
from multiple regions and sources. The following sections will describe the data 
collection and the experiments design in detail.  
2.2  Data Collection 
This section described the database that was used in all experiments. Through 
multiple international trips to China and traveling within China, I have personally 
developed relationships with several large insurance companies, state health insurance 
agencies and hospitals for this research collaboration. After many rounds of presentations, 
communications and negotiations, several companies and hospitals were willing to offer 
at least two consecutive years of de-identified data of all patients that they had served for 
this study anonymously due to business operational concerns. After signing the 
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appropriate data use agreements, we obtained the data from three commercial insurance 
companies and three hospitals. The final collected data from all sources consisted of a 
total of 884,289 people with 1,983,595 claims. However, not all of the collected data 
were used in this study and the reasons were explained in the data sections of each data 
source below. The requested necessary information of each individual for this project was 
a unique de-identified tracking number of the person, age, sex, diagnostic codes, and the 
health expenditure associated each diagnosis. Data from some sources may contain 
supplementary information for each patient such as the hospital information, the type of 
received care, and the type of the insurance. Because the data was extracted from claims 
of the insurance companies and the inpatient records of the hospitals, it did not contain 
any healthy users who did not utilize health services in a given year. The resulting data 
sets from all sources do not contain any personal identifiable information. The following 
sections will describe the data from each source in detail. 
Insurance Company A 
The insurance company A (IA) has multi-province health insurance business 
operations. The dataset from the insurance company A consisted of a total of 492,635 
people with 1,180,323 claims of health insurance over a time span of four years (2009-
2012). The data for 2012 only contained half a year’s records due to the time of data 
request. The underwriting populations of the data from the insurance company A were 
from three major cities in China where the population in each city was greater than 10 
million. However, the people in the health plan may have the freedom to seek care in 
other provinces or cities. There were a total of 59,458 people with 162,740 claims in the 
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year 2009, 138,903  people with 294,770 claims in the year 2010, 212,455 people with 
590,348 claims in the year 2011, and 81,819 people with 132,465 claims in the year 2012 
( 6 months). The types of hospital and health insurance were recorded for each patient. 
The data from 2009 and 2012 of insurance company A was excluded from the study for 
the following reasons. First, in the year 2009, the number of the people was limited 
compared with the number of people from other years and in the year 2012, the data 
contained only half a year’s records. Second, not all insurance companies or hospitals 
supplied data in the year 2009 or in the year 2012, which may not provide useful 
information for the cross-sectional comparisons for similar years.     
Insurance Company B  
The insurance company B (IB) focuses on employer based group health insurance 
plans in several provinces. The serviced population was fairly stable and smaller 
compared with other participating companies. The dataset from company B contained a 
total of 10,961 people with 20,640 claims over four years. Other than the necessary 
information requested by the researcher, no supplementary information was provided 
from this company. There were 2,489 people with 5,371 claims in the year 2009, 3,009 
people with 5,665 claims in the year 2010, 3,408 people with 6,340 claims in the year 
2011 and 2,055 people with 3,264 claims in the year 2012 (6 months). Although the 
number of people of data in the year 2009 was similar with other years of insurance 
company B, in order to compare with the data from all sources, data in the year 2009 and 
2012 were also excluded from the study.      
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Insurance Company C 
The insurance company C (IC) is a state owned insurance company offering 
health insurance products with multi-province operations. The dataset from company C 
included a total of 203,013 people with 591,690 claims from three years (2010-2012).  
Hospital indicators were also provided as supplementary information. There were 12,946 
people with 36,800 claims in the year 2010, 139,645 people with 368,366 claims in the 
year 2011 and 50,422 people with 186,524 claims in the year 2012 (9 months). For the 
similar reasons above, data in the year 2012 was excluded in this study.   
Hospital A 
 The hospital A (HA) is a first-class tertiary major medical center in a city with a 
population more than two million in northern China. With more than 2000 beds, this 
hospital is one of the best hospitals in the province that offers comprehensive medical 
services ranging from medical care, medical education, research, and preventable care.  
The hospital has approximately 900,000 outpatient and emergency visits, 50,000 
inpatient admission, and 2500 surgical operations every year. The dataset from hospital A 
only contained inpatient data of 86,327 people with 94,470 admissions from two 
consecutive years (2010, 2011) because the diagnosis and patient ID in the outpatient 
data were not well recorded. There were 41,940 people with 45,407 admissions in the 
year 2010, and 44,387 people with 49,063 admissions in the year 2011. Information other 
than that requested by the researchers for the study was not provided by hospital A.   
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Hospital B 
 The hospital B (HB) is a first-class tertiary major medical center of a city with a 
population more than two million in northern China. The hospital offers comprehensive 
services ranging from medical care, medical education, research, physical therapy, and 
preventable care. With an approximate total patient capacity of 1500 beds, the hospital 
has approximately one million outpatient visits, 40,000 inpatient admissions, and 15,000 
operating cases every year. With similar reasons for the outpatient population, the dataset 
from the hospital B only contained inpatient data of 60,759 people with 64,413 records 
over two consecutive (2010, 2011). There were 29,238 people with 31,027 admissions in 
the year 2010, and 31,521 people with 33,386 admissions in the year 2011. 
Supplementary information other than what was requested by the researchers for the 
study was not provided by hospital B.   
Hospital C 
The hospital C (HC) is a second-class tertiary comprehensive medical center 
located in a southern China city with a population more than 10 million. With a total 
patient capacity of approximately 700 beds, the hospital has a facility of 48,000 square 
meters (510,000 square feet) serving both the city and some rural areas around the city.  
With the similar reason, the dataset from hospital C only contained inpatient data of 
30,594 people with 32,059 records from two consecutive years (2010, 2011). There were 
14,151 inpatient admissions in the year 2010. However, no unique patient identifier was 
provided for that year due to technique issues. There were 16,443 people with 17,908 
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admissions in the year 2011. Supplementary information included clinical management 
data elements such as the name of surgical procedures, inpatient days, and the cost by 
clinical components.   
2.3 Data Process 
 As the requested data for the proposed study was from multiple sources and 
locations, different formats, structures and tracking systems were used in the datasets.  
Thus, the first step to process the data was to standardize all the data into a unified format.  
We first converted all of the data into CSV format and categorized the file by year and 
source. Then, within each file, we created two sets of unique tracking ID systems for each 
patient and each claim across all the data sets based on the year, source, and location.  
Additional data attributes for source, location and year within the file were also created 
for the ease of analysis. Because of the scale of the data, we imported all data into a 
relational database in SQL as several tables to speed and extend the capacity of data 
processing. Then from the aggregated database, we can create subsets of the data easily 
according to research interests. The variable of sex was converted to categorical format as 
1 (male) and 0 (female). The digital numbers after the dot of the ICD codes in the 
variable of diagnosis were removed for the data from hospitals because they were added 
by the hospital clinical information systems for internal management purpose or modified 
for local users. Data validation was conducted by checking the existence of the analytical 
core components: age, gender, diagnostic codes and the costs on each patient level and 
searching duplicated records. If one of these components was missing or a duplicated 
record was found, then the patient or the claim would be recorded and excluded from the 
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study. The final data used in the analysis for this study included the data from all sources 
in 2010 and 2011.  
2.4 Experiment Design 
2.4.1 Conceptual Framework 
Investigating the adaptability of the ACG system to new countries or health 
organizations are usually classified into three steps. The first step is to investigate the 
feasibility of the ACG system for a local diagnostic coding system from healthcare data 
such as health insurance claim, EHR.
28,35,60
 This step involves testing whether the 
required data elements from the local health system can be recognized by the ACG 
system. If the local coding system is not feasible to use ACG system directly, the 
crosswalk mapping method may be applied to translate the local code to the 
corresponding ICD-10 code. This step was conducted in the experiments for aim 1.  
The second step, which is frequently used in many previous validation 
studies,
25,49,51, 54,55
 is to test the validity of the ACG system to describe the disease burden 
of the studied population from the concept of morbidity, or comorbidity by examining the 
distributions of the classifications for the patients from the ACG system, such as ADG or 
ACG, and comparing these results to some known diagnoses, benchmarks or prevalence 
data. This information can provide important inference on whether the ACG system 
classifies individuals from a population into the right categories. This step was conducted 
in experiments for aim 2.  
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The third step is to quantitatively investigate the performance of the ACG system 
on the explanatory ability for the variables of research interests in retrospective and 
prospective studies. This step also checks the consistency of the explanatory ability 
across years and interprets the risk adjustment models. This step was performed in the 
experiments for aims 3. After the validation study, researchers usually explore 
applications based on the ACG system, such as predictive modeling and physician 
profiling.   
2.4.2 Experiment Design and Research Method for Aim 1 
Aim 1: Assess the feasibility of the diagnosis based risk adjustment method to the 
Chinese health insurance data.  
To achieve aim 1, the results from the ACG system were analyzed both 
qualitatively and quantitatively. To test the overall process ability of the risk adjustment 
instrument - the ACG system for the Chinese healthcare system, the data from insurance 
companies and hospitals at inpatient setting were both used. The subsets of the data were 
prepared in three levels. The first level was at each specific source level in which each 
dataset contained the data from a particular insurance company or a hospital in a full 
given year. The second level was at an aggregated type of the data level in which each 
dataset contained a full year’s data from all insurance companies or hospitals. The third 
level was all data from a type of the data in which each dataset contained two years’ data 
from all insurance companies or all hospitals. The basic summary of the statistics for the 
datasets used in the analyses was reported. 
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The ACG system (Version 10.0) was applied to these data sets to obtain the 
classification results respectively. Input data elements for the ACG system included the 
tracking ID, age, sex, total healthcare expenditures and diagnostic codes for each patient.  
The feasibility of the ACG system for the data from the Chinese healthcare system was 
investigated based on those created data sets. The percentage of unrecognized diagnoses 
which is a frequently reported parameter in previous ACG validation studies, are often 
used to evaluate the feasibility of the ACG system to a new setting for direct usage. We 
investigated the unrecognized diagnostic codes and reported the quality of the diagnostic 
codes by measuring the percentage of the unrecognized diagnoses. The percentage of the 
unrecognized diagnoses was summarized according to 3 levels: 1) each specific insurance 
company or hospital per year; 2) all insurance companies or all hospitals per year and 3) 
all insurance companies or hospitals in a two-year time span.  
2.4.3 Experiment Design and Research Method for Aim 2 
Aim 2: Analyze the disease burden morbidity pattern of the patient populations of 
insurance companies and hospitals. 
The frequency distributions of the ADGs, total numbers of ADGs, ACGs, and 
relative degree of healthcare expenditures by the ACGs were reported across years, 
according to data of the populations of the specific sources and the types (insurance 
company or hospital). The similarity of the distributions was compared qualitatively for 
each source of the data between two consecutive years and assessed across different 
sources and types of the data. The difference in distributions among different sources, 
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types of data was also reported. The unobserved ACGs and ADGs of each specific data 
source as well as for the aggregated data of each data type were summarized.     
2.4.4 Experiment Design and Research Method for Aim 3 
Aim 3: Evaluate the performance of the risk adjustment method on the explanatory 
ability of the healthcare cost for different regions and sources of data in the Chinese 
healthcare system. Provide recommendations on implementation of the risk adjustment 
method and explore applications based on the risk adjustment result. 
 To achieve aim 3, several multivariate regression models were built to assess the 
overall performance of the diagnosis-based risk adjustment method for healthcare cost.  
As mentioned earlier, through the mapping algorithm of the ACG system, patients can be 
classified under either the ADG category, or the ACG category. Both categories were 
used to build the regression model. Under the ADG category, each patient is classified 
into one or more of the 32 ADG categories non-exclusively. This means that a patient 
could be present in multiple ADG categories depending on the diagnoses that the patient 
may have over a year. Under the ACG category, each patient is classified into one of the 
105 ACG categories exclusively even if there are multiple diagnoses that the patient may 
process. The ADG category is easier to build the regression model as it has fewer 
variables than the ACG category but the ACG category is easier to interpret the results of 
the regressions and to perform further actuarial analysis as each patient is replaced into 
one of the ACG actuarial cells exclusively.   
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To evaluate the performance of the risk adjustment method on the explanatory 
ability of healthcare expenses, the adjusted coefficient of determination (R
2
) was used as 
a measurement. A set of the adjusted R
2
s was obtained of each year based on the datasets 
of interest from the following multivariate regression models among which the dependent 
variable was the total healthcare expense of a patient in a given year and the independent 
variables varied depending on the model. Model 1: without any morbidity information, 
age and sex were the only independent variables; Model 2: Age, sex and the ADG 
categories were the independent variables; Model 3: Only the ACGs categories were the 
independent variables. Within each multivariate regression model, the adjusted R
2 
for 
each source according to the years was obtained, using the datasets derived from the 
experiment for research aim 1. The obtained R
2
s were compared from the three models 
using various datasets. In addition, the R
2
s were compared within the same source for two 
consecutive years and across different sources and types of data across years. If there 
were significant differences between the R
2
 values across years within the same model 
using the similar datasets, the difference would be investigated and explained. 
  The variable of healthcare expenditures is usually continuous, positive, and 
skewed positively with non-constant variance because the healthcare expenditures of 
most people in a population tend to be low; however it can be significantly high for a few 
high cost users that consume significantly more healthcare resources than the population 
average. This phenomenon results in a departure of the healthcare expenditure data from 
the normal distribution.
61
 Therefore, in the regression analysis, the total health 
expenditure of each patient, the dependent variable, was transformed into the log format 
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in order to achieve an approximate normal distribution of the data for the healthcare 
expenditures. The sex, ADGs and ACGs variables in the regression models were treated 
as dummy variables, with a notation of 1 or 0 for male and female in the sex variable and 
the notation of 1 or 0 for the presence of a category for that patient or not in the ADGs 
and ACGs variable.  
After different regression models were obtained, a set of analyses on categorical 
multivariate regression models were performed. The focus was on interpreting the 
coefficients derived from the multivariate regression model that utilizes the ACG 
categories as the explanatory variables (model 3). This model was chosen because each 
patient was exclusively assigned into one of the ACG actuarial cells under such a model, 
resulting in a clear and straightforward interpretation of the healthcare costs of a 
population, or an individual. In order to interpret the results from the multivariate 
regression model on categorical data, an appropriate ACG category among the 105 
possibilities was selected as a reference group for categorical data analysis. One 
coefficient of an ACG category was interpreted as the estimated mean total healthcare 
cost for that ACG category in a population. The relative risk was defined as the ratio of 
the actually observed health expenditure of one ACGs category to the health expenditure 
of the population average. Thus, we could not only quantify the expected cost of each 
ACG category for a given year, but also could obtain the relative orders and changes of 
all ACG categories in term of the expected and observed health expenditures among 
different populations, organizations, and locations.  
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 Furthermore, by reviewing ACG studies conducted in other countries, the 
coefficients of the ACG categories can be compared internationally to provide knowledge 
in healthcare expenditures between countries from the perspective of a particular clinical 
category. However, the coefficients of the ACG categories are not frequently reported in 
the literature from an actuarial science perspective. To solve this issue, we used the 
reference data derived from the ACG system, which was based on a nationwide 
commercial insurance population with comprehensive benefits from the United States to 
compare the similarities and differences of the relative risk of various ACGs between 
commercial insured populations between China and the United States. 
Based on the results from the experiments for aim 1-3, a comprehensive summary 
of the feasibility and performance of the ACG system in the Chinese healthcare system 
were reported. The issues and problems when applying the risk adjustment method from 
the ACG system to the Chinese healthcare system were also investigated. Based on the 
characteristics of the Chinese healthcare system and the healthcare policy, 
recommendations and analyses on how the risk adjustment method could be applied to 
the Chinese healthcare system for potentially improving the efficiency, equity and quality 
of the care were discussed. Several applications based on the risk adjustment method 
from the ACG system and demonstrate the potential values of these tools to solve 
healthcare problems based on the available healthcare data, such as the predicative 
modeling, resource utilization classifications, disease burden distributions, and risk scores 
were explored.   
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3 RESULTS 
3.1 Demographics  
 Overall, a total of 510,366 people aggregated from 3 insurance companies and 
177,680 people aggregated from 3 hospitals in 2010 and 2011 fulfilled the data 
requirement for the diagnosis-based risk analysis. The mean age and the percentage of 
males in the aggregated population from the insurance companies in 2010 were 33.13 
years and 48.83% respectively, and in 2011 they were 29.71 years and 47.71% 
respectively. In contrast, the mean age and percentage of males in the aggregated 
population from hospitals in 2010 were 45.45 and 49.08% respectively and in 2011 they 
were 45.62 and 48.45% respectively. Specifically, Table 3.1 summarized the 
demographics by companies according to the years. In 2010, the mean and median of the 
total expenditures for the population from insurance companies were 4,015 RMB and 911 
RMB respectively, while the mean and median for the population from hospitals were 
12,083 RMB and 6,642 RMB respectively. Similarly, in 2011, the mean and median of 
the total expenditures of the population from insurance companies were 3,385 RMB and 
977 RMB while the mean and median of the population from hospitals were 13,459 RMB 
and 7,196 RMB respectively.  
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Table 3.1 Demographics and Descriptive Statistics of Healthcare Expenditures for the Insurance Companies (n=3) and 
Hospitals (n=3) 
Source Year 
Mean 
Age 
Median 
Age 
Age 
Range 
Seniors 
% 
(>=65) 
Male% 
Patient 
Count 
Mean Cost           
(Chinese Yuan ¥ | 
U.S Dollar $) 
Median Cost      
(Chinese Yuan ¥  | 
U.S Dollar $) 
IA  
2010 31.4 31 0-100 4.7% 48.2% 138,903 ¥2772 $426 ¥693 $107 
2011 28.5 29 0-111 2.0% 46.5% 212,455 ¥2,856 $439 ¥924 $142 
IB 
2010 30.9 32 1-84 0.4% 43.8% 3,009 ¥2,083 $320 ¥803 $124 
2011 27.4 30 1-66 0.0% 42.1% 3,408 ¥1,764 $271 ¥758 $117 
IC 
2010 52.2 53 0-109 26.4% 56.7% 12,946 ¥17,796 $2,738 ¥5,686 $875 
2011 31.6 31 0-100 4.9% 49.7% 139,645 ¥4,230 $651 ¥835 $128 
HA 
2010 46.4 50 0-110 26.0% 48.4% 41,940 ¥13,100 $2,015 ¥7,322 $1,126 
2011 47.3 51 0-98 26.3% 47.9% 44,387 ¥14,819 $2,280 ¥8,025 $1,235 
HB 
2010 41.0 42 1-102 20.0% 49.9% 29,238 ¥11,806 $1,816 ¥5,989 $921 
2011 40.4 41 1-104 19.6% 49.0% 31,521 ¥12,721 $1,957 ¥6,246 $961 
HC 
2010 51.8 52 0-110 27.1% 49.4% 14,151 ¥9,639 $1,483 ¥6,230 $959 
2011 51.1 51 0-101 25.3% 48.9% 16,443 ¥11,201 $1,723 ¥6,976 $1,073 
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3.2 Feasibility  
 A total of 1,302,289 health insurance claims corresponding to 6,628 unique ICD-
10 codes were aggregated from 3 insurance companies and a total of 190,942 inpatient 
health expenditure records corresponding to 1,057 unique ICD-10 codes were aggregated 
from inpatient discharge reports of 3 hospitals in 2010 and 2011. This data was submitted 
to the ACG system in order to test the feasibility of the ACG system to the Chinese 
health insurance coding system. The average diagnostic codes per patient per year were 
2.55 and 1.07 for patients from insurance companies and hospitals respectively. Table 3.2 
summarized the total number of diagnoses per year, total number of unique diagnoses per 
year, average diagnoses per patient per year and the percentage of the unknown diagnoses 
per year according to sources and years.   
Table 3.2 Distributions of Diagnoses by Sources and Years 
Source Year 
Number of 
Claims/Diagnoses 
Unique 
Diagnoses  
Average Number of 
Unique Diagnoses per 
Patient  
Percentage of 
Unknown 
Diagnoses  
IA 
2010 294,770 3,742 1.96 2.2 
2011 590,348 4,988 2.39 3.7 
IB 
2010 5,665 456 1.88 0.6 
2011 6,340 448 1.86 0.1 
IC 
2010 36,800 1,349 2.84 0.1 
2011 368,366 4,371 2.64 0.4 
HA 
2010 45,407 747 1.04 5.8 
2011 49,063 781 1.05 5.0 
HB 
2010 31,027 827 1.02 0.5 
2011 33,386 802 1.02 0.3 
HC 
2010 14,151 645 1 0.2 
2011 17,908 680 1.04 0.1 
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 From all sources (insurance companies and hospitals), the weighted average rate 
of unrecognized diagnostic codes over 2 years was less than 2.5%. Specifically, less than 
2.3% of the study populations from the insurance companies and less than 3% of the 
study populations from hospitals were unclassifiable by the ACGs system over the 2 
years. For a given year, the rates of unrecognized diagnostic codes for the populations 
from insurance companies and hospitals were less than 3.8% and 5.8% respectively. The 
rate of unrecognized diagnostic codes of all populations from the insurance companies 
and of most of the populations from the hospitals were not higher than the 5% threshold, 
which is recommended by the ACGs system, for considering the feasibility of the 
diagnostic code to the ACGs system. Only the data from the source HA, a hospital, 
resulted in 5.8% and 5% rate of the unrecognized diagnostic codes in 2010 and 2011 
respectively, which was equal or slightly higher than the 5% threshold of concerning the 
feasibility of the coding system using the ACGs system.    
3.3 Morbidity Burden 
3.3.1 Number of ADGs 
 Table 3.3 presented the proportions of patient populations of insurance companies 
and hospitals according to the total number of total ADGs per patient in 2010 and 2011. 
The populations of the insurance companies possessed a higher proportion of the patients 
with multiple ADGs than the patient populations of the hospitals. The diversity of the 
patients, which was measured by the number of ADGs per patient, of the insurance 
companies was higher than that was for the patient populations of the hospitals. For 
example, the number of ADGs per patient was ranged from 0 ADGs to 15+ ADGs for the 
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patient populations of the insurance companies. By contrast, the range was only 0 ADG 
to 5 ADGs for the patient populations of the hospitals. Moreover, more than 95% of the 
patient populations of the hospitals were concentrated in one category, patients with 1 
ADG, resulting in a very small percentage of patient populations assigned into other 
categories in terms of the number of ADGs.     
 The total number of ADGs per patient summarized the overall morbidity burden 
of a patient. In general, it is expected that the number of the ADGs indicates the degree 
and complexity of the morbidity burden. The distributions of the number of ADGs in two 
years indicated that the overall morbidity burden for the populations of insurance 
companies was higher and more complex than it was for the hospital populations. In 
addition, the disease burden of the populations of insurance companies was more diverse 
than it was for the hospital populations.  
Table 3.3 Distributions of the Numbers of ADGs per Patient by Sources and Years 
(Unit: Population Percentage) 
                                            Types of Data   
 
 Number of ADGs                          Years 
Percent of Aggregated 
Insurance Populations 
Percent of Aggregated 
Hospital Populations 
2010 2011 2010 2011 
Patients with  0 ADG 1.356 1.382 2.848 2.251 
Patients with  1 ADG 48.784 62.163 95.480 95.286 
Patients with  2 ADGs 23.111 17.595 1.590 2.323 
Patients with  3 ADGs 12.564 8.191 0.077 0.131 
Patients with  4 ADGs 6.802 4.563 0.005 0.008 
Patients with  5 ADGs 3.600 2.653 n/a 0.001 
Patients with  6 ADGs 1.899 1.572 n/a n/a 
Patients with  7 ADGs 0.947 0.940 n/a n/a 
Patients with  8 ADGs 0.490 0.514 n/a n/a 
Patients with  9 ADGs 0.239 0.240 n/a n/a 
Patients with 10 ADGs 0.117 0.102 n/a n/a 
Patients with 11 ADGs 0.053 0.049 n/a n/a 
Patients with 12 ADGs 0.025 0.018 n/a n/a 
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Patients with 13 ADGs 0.007 0.012 n/a n/a 
Patients with 14 ADGs 0.003 0.003 n/a n/a 
Patients with 15+ ADGs 0.002 0.002 n/a n/a 
 
3.3.2 ADGs Distributions  
3.3.2.1 Aggregated Populations 
 The distributions of the patient populations of insurance companies and hospitals 
according to the 32 ADGs were presented in Table 3.4. In the system, originally 34 
ADGs markers were designed. However, only 32 ADGs markers, which still maintained 
their original numerical name, are currently in use. In 2010, the patients from the 3 
insurance companies generated 275,140 ADGs whereas the patients from the 3 hospitals 
generated 84,400 ADGs. In 2011, the patients from the 3 insurance companies generated 
726,010 ADGs whereas the patients from the 3 hospitals generated 92,684 ADGs. All 
possible ADG markers were observed in the patient populations aggregated from the 3 
insurance companies in both 2010 and 2011, whereas only 31 kinds of ADGs markers 
were observed in the patient populations aggregated from the 3 hospitals in 2010 and 
2011. Specifically, ADG 17, named as “Chronic Specialty: Unstable-Ear, Nose, Throat” 
did not presented in the populations aggregated from 3 hospitals at all, in neither of 2010 
nor 2011.  
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Table 3.4 Distributions of the ADGs Aggregated by Insurance Companies or 
Hospitals according to Years (Unit: Population Percentage)  
 
 The patterns of the ADGs distributions were different between patient populations 
of insurance companies and hospitals. The 5 most frequent ADG categories for the 
patient populations aggregated from the 3 insurance companies in 2010 were ADG 2,  
Time Limited: Minor-Primary Infections (33.56%), ADG 31, Prevention/Administrative 
                                                          Type of Source 
                                                                        
                                                                      Year 
                               ADG Category 
Insurance Companies Hospitals 
2010 2011 2010 2011 
1 Time Limited: Minor 10.01 14.35 2.37 2.49 
2 Time Limited: Minor-Primary Infections 33.56 37.69 9.62 9.29 
3 Time Limited: Major 1.61 2.03 5.84 5.72 
4 Time Limited: Major-Primary Infections 2.42 3.18 2.14 2.12 
5 Allergies 1.71 2.90 0.01 0.01 
6 Asthma 0.82 1.04 0.43 0.45 
7 Likely to Recur: Discrete 10.49 13.88 3.17 3.21 
8 Likely to Recur: Discrete-Infections 5.65 8.67 0.99 0.95 
9 Likely to Recur: Progressive 1.24 0.60 6.55 6.61 
10 Chronic Medical: Stable 14.16 12.74 8.24 8.84 
11 Chronic Medical: Unstable 5.00 4.24 12.45 13.55 
12 Chronic Specialty: Stable-Orthopedic 0.79 1.05 0.41 0.45 
13 Chronic Specialty: Stable-Ear,Nose,Throat 0.42 0.60 0.41 0.45 
14 Chronic Specialty: Stable-Eye 0.92 0.77 0.78 0.83 
16 Chronic Specialty: Unstable-Orthopedic 0.12 0.20 0.14 0.10 
17 Chronic Specialty: Unstable-Ear,Nose,Throat 0.00 0.01  n/a  n/a 
18 Chronic Specialty: Unstable-Eye 0.20 0.20 0.27 0.26 
20 Dermatologic 3.12 4.22 0.38 0.33 
21 Injuries/Adverse Effects: Minor 2.50 5.45 3.80 3.66 
22 Injuries/Adverse Effects: Major 1.39 2.34 5.20 4.82 
23 Psychosocial: Time Limited, Minor 0.46 1.09 0.02 0.03 
24 Psychosocial:Recurrent or Persistent,Stable 0.41 0.45 0.18 0.23 
25 Psychosocial:Recurrent or Persistent,Unstable 0.11 0.13 0.05 0.05 
26 Signs/Symptoms: Minor 18.78 29.07 2.09 2.11 
27 Signs/Symptoms: Uncertain 21.90 22.04 5.50 5.28 
28 Signs/Symptoms: Major 2.97 3.31 3.48 3.66 
29 Discretionary 2.14 3.09 8.67 8.50 
30 See and Reassure 0.49 1.04 0.13 0.16 
31 Prevention/Administrative 21.98 13.40 4.78 4.97 
32 Malignancy 0.95 0.52 3.13 3.89 
33 Pregnancy 2.38 2.20 7.63 7.30 
34 Dental 9.00 11.73 0.01 0.02 
Total Number of ADGs 275,140 726,010 84,400 92,684 
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(21.98%), ADG 27, Signs/Symptoms: Uncertain (21.9%),  ADG 26, Signs/Symptoms: 
Minor (18.78%), and ADG 10, Chronic Medical: Stable (14.16%);  in 2011, these 
markers for the patient populations from  insurance companies were ADG 2, Time 
Limited: Minor-Primary Infections (37.69%), ADG 26, Signs/Symptoms: Minor 
(29.07%), ADG 27, Signs/Symptoms: Uncertain (22.04%), ADG 1, Time Limited: Minor 
(14.35%), and ADG 7, Likely to Recur: Discrete (13.88%). In contrast, the 5 most 
frequent ADG markers for the patient populations aggregated from the 3 hospitals in 
2010 were ADG 11, Chronic Medical: Unstable (12.45%), ADG 2, Time Limited: Minor-
Primary Infections (9.62%), ADG 29, Discretionary (8.67%), ADG 10, Chronic Medical: 
Stable (8.24%), and ADG 33, Pregnancy (7.63%); in 2011, these markers for the patient 
populations from hospitals were ADG 11, Chronic Medical: Unstable (13.55%), ADG 2, 
Time Limited: Minor-Primary Infections (9.29%), ADG 10, Chronic Medical: Stable 
(8.84%), ADG 29 Discretionary (8.5%), ADG 33, Pregnancy (7.3%).   
 Among the 5 most frequent ADG categories in 2010 and 2011 for the patients of 
the insurance companies, markers - such as ADG 2, ADG 26, and ADG 27 - presented in 
both years. The 5 most frequent ADGs markers remained the same for the populations 
from the hospital, with only a switch in the order of ADG 10 and ADG 29 between 2010 
and 2011.    
 Figure 3.1 showed the comparison of the distributions of ADG markers in 2010 
and 2011 for the patients from the insurance companies. The general pattern of the 
frequency distributions according to the ADGs was similar between 2010 and 2011 for 
the patient populations from the 3 insurance companies.  
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Figure 3.1  Distributions of the Population Aggregated from All Insurance 
Companies according to ADGs in Two Years   
 
 Figure 3.2 showed the comparison of the distributions of ADG markers in 2010 
and 2011 for the patients from the hospitals. The general pattern of the frequency 
distributions according to the ADGs was similar between 2010 and 2011 for the patient 
populations from the 3 hospitals.  
Figure 3.2 Distributions of the Population Aggregated from All Hospitals according 
to ADGs in Two Years 
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 Comparing Figure 3.1 and Figure 3.2, it was obvious that the distribution patterns 
of the ADGs were quite different for the populations between the insurance companies 
and hospitals. In general, the distribution of the ADGs was significantly less frequent for 
the populations of the hospitals than it was for the populations of the insurance 
companies. However, the frequency for some ADG categories was higher in the 
populations of the hospitals than it was for the populations of the insurance companies, 
such as ADG 33, pregnancy, ADG 9, likely to recur: discrete-infections, ADG 11, 
chronic medical: unstable etc.        
3.3.2.2 Specific Insurance Companies 
 Table 3.5 summarized the ADGs distributions of the populations in frequency 
percentage of specific insurance companies according to years. At the company level, 
comparing with each company’s own distribution in two consecutive years, both 
insurance companies A and B (IA, IB) had relatively similar frequency distributions of 
the populations across two years. Moderate difference existed in insurance company C 
(IC).    
Table 3.5 Distributions of ADGs by Insurance Companies and Years (Unit: 
Population Percentage) 
ADG 
Number 
ADG Description 2010 
IA 
 
2011 
IA 
 
2010 
IB 
 
2011 
IB 
 
2010 
IC 
2011 
IC 
1 Time Limited: Minor 9.69 10.54 17.31 20.80 11.80 19.99 
2 Time Limited: Minor-Primary 
Infections 
34.31 38.19 44.27 46.63 23.06 36.70 
3 Time Limited: Major 1.48 2.29 1.83 1.82 2.90 1.64 
4 Time Limited: Major-Primary 
Infections 
2.34 3.31 2.92 2.93 3.13 3.00 
5 Allergies 1.75 2.92 1.73 1.20 1.20 2.89 
6 Asthma 0.79 1.02 1.00 0.85 1.10 1.08 
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7 Likely to Recur: Discrete 10.17 14.09 11.33 11.12 13.76 13.62 
8 Likely to Recur: Discrete-
Infections 
5.84 9.92 6.38 6.34 3.53 6.84 
9 Likely to Recur: Progressive 0.48 0.37 0.27 0.09 9.63 0.97 
10 Chronic Medical: Stable 12.74 13.31 7.51 7.25 30.92 12.02 
11 Chronic Medical: Unstable 3.58 3.65 2.29 2.38 20.86 5.17 
12 Chronic Specialty: Stable-
Orthopedic 
0.64 0.52 0.50 0.47 2.47 1.87 
13 Chronic Specialty: Stable-
Ear,Nose,Throat 
0.39 0.38 0.76 0.65 0.75 0.93 
14 Chronic Specialty: Stable-Eye 0.86 0.50 0.40 0.79 1.72 1.19 
16 Chronic Specialty: Unstable-
Orthopedic 
0.12 0.25 0.10 0.06 0.14 0.13 
17 Chronic Specialty: Unstable-
Ear,Nose,Throat 
0.01 0.01 n/a n/a n/a 0.01 
18 Chronic Specialty: Unstable-
Eye 
0.16 0.16 0.27 0.26 0.70 0.27 
20 Dermatologic 3.05 3.73 3.95 3.76 3.75 4.98 
21 Injuries/Adverse Effects: Minor 2.40 4.16 8.31 8.01 2.19 7.35 
22 Injuries/Adverse Effects: Major 1.32 2.01 3.29 2.99 1.68 2.81 
23 Psychosocial: Time Limited, 
Minor 
0.45 0.71 0.03 0.03 0.57 1.70 
24 Psychosocial:Recurrent or 
Persistent,Stable 
0.38 0.46 0.03 0.18 0.87 0.45 
25 Psychosocial:Recurrent or 
Persistent,Unstable 
0.11 0.16 n/a n/a 0.24 0.08 
26 Signs/Symptoms: Minor 18.77 32.51 17.58 12.85 19.17 24.22 
27 Signs/Symptoms: Uncertain 21.20 17.32 15.25 13.00 30.91 29.44 
28 Signs/Symptoms: Major 2.89 3.08 6.25 5.87 3.03 3.60 
29 Discretionary 1.96 2.96 3.16 3.26 3.78 3.27 
30 See and Reassure 0.50 1.15 0.07 0.88 0.52 0.88 
31 Prevention/Administrative 22.03 12.89 0.63 0.85 26.43 14.50 
32 Malignancy 0.54 0.44 0.43 0.47 5.40 0.63 
33 Pregnancy 2.61 2.58 0.27 0.35 0.44 1.67 
34 Dental 9.35 12.38 7.38 8.07 5.60 10.83 
 Total Number of ADGs 240,185 420,571 4,980 5,596 29,975 299,843 
 
 Figure 3.3 showed the distributions of ADGs of insurance company A (IA) in 
2010 and 2011. In total, 240,815 and 420,571 ADGs respectively, were generated from 
its populations in 2010 and 2011. For insurance company A (IA), all ADG categories 
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were observed in the populations for both years. Most of the ADG categories presented 
similar frequency distributions within two years, except for ADG 26 and ADG 31. For 
both years, the most frequent ADG were ADG 2, with the least frequent being ADG 17.  
Figure 3.3 ADGs Distributions of Insurance Company A (IA) in Two Years 
 
 Figure 3.4 showed the distributions of ADGs for the insurance company B (IB) in 
2010 and 2011. In total, 4,980 and 5,596 ADGs were generated in 2010 and 2011 
respectively. For insurance company B (IB), ADG 17, Chronic Specialty: Unstable-Ear, 
Nose, Throat was not observed neither in 2010 nor 2011. All ADG categories presented 
similar frequency distributions within two years. ADG 2 was the most frequent ADGs for 
both years. In 2010, the two least frequent ADGs were ADG 23, Psychosocial: Time 
Limited, Minor, and ADG 24, Psychosocial: Recurrent or Persistent, Stable, both of 
which showed the same frequency.  In 2011, the least frequent ADG was ADG 23.   
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Figure 3.4 ADGs Distributions of Insurance Company B (IB) in Two Years 
 
 Figure 3.5 showed the distributions of ADGs for insurance company C (IC) in 
2010 and 2011. In all, 29,975 and 299,843 ADGs were generated in 2010 and 2011 
respectively. For insurance company C (IC), ADG 17, Chronic Specialty: Unstable-Ear, 
Nose, Throat was not observed in 2010. In 2010, the most and least frequent ADGs in the 
population were ADG 10, Chronic Medical: Stable, and ADG 16, Chronic Specialty: 
Unstable-Orthopedic respectively. In 2011, all ADGs were observed for the population. 
The most and least frequent ADGs were ADG 2 and ADG 17 respectively. Overall, 
comparing two years’ frequency distributions of ADGs, variations in some ADGs were 
observed.   
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Figure 3.5 ADGs Distributions of Insurance Company C (IC) in Two Years 
 
3.3.2.3 Specific Hospitals 
 Table 3.6 summarized the ADGs distributions of the populations in frequency 
percentage of specific hospitals according to years. At the hospital level, comparing each 
hospital’s own distribution in two consecutive years, all hospitals had relatively similar 
frequency distributions of the populations according to the ADGs across two years.  
However, some differences existed in the distributions of the ADGs among the 3 
hospitals. All ADGs were observed in the inpatient populations from the 3 hospitals 
except for the ADG 17, Chronic Specialty: Unstable-Ear, Nose, Throat.  
Table 3.6 Distributions of ADGs by Hospitals and Years (Unit: Population 
Percentage) 
ADG 
Number 
ADG Description 
2010 
HA 
2011 
HA 
2010 
HB 
2011 
HB 
2010 
HC 
2011 
HC 
1 Time Limited: Minor 1.64 1.67 3.93 4.15 1.30 1.50 
2 
Time Limited: Minor-
Primary Infections 
13.79 12.53 6.52 7.62 3.64 3.73 
3 Time Limited: Major 6.21 5.86 6.58 6.68 3.24 3.52 
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4 
Time Limited: Major-
Primary Infections 
1.55 1.38 2.45 2.48 3.25 3.45 
5 Allergies  n/a 0.01  n/a 0.00 0.04 0.03 
6 Asthma 0.21 0.17 0.84 0.92 0.21 0.29 
7 Likely to Recur: Discrete 2.90 2.88 2.29 2.11 5.79 6.19 
8 
Likely to Recur: Discrete-
Infections 
0.42 0.34 0.54 0.39 3.63 3.67 
9 Likely to Recur: Progressive 9.08 9.56 5.06 4.49 2.13 2.69 
10 Chronic Medical: Stable 7.50 8.07 9.03 10.12 8.79 8.48 
11 Chronic Medical: Unstable 13.92 15.98 10.67 10.94 11.78 11.99 
12 
Chronic Specialty: Stable-
Orthopedic 
0.40 0.53 0.29 0.20 0.73 0.74 
13 
Chronic Specialty: Stable-
Ear,Nose,Throat 
0.37 0.46 0.45 0.46 0.49 0.41 
14 
Chronic Specialty: Stable-
Eye 
1.18 1.16 0.42 0.40 0.34 0.77 
16 
Chronic Specialty: Unstable-
Orthopedic 
0.23 0.14 0.03 0.05 0.12 0.10 
17 
Chronic Specialty: Unstable-
Ear,Nose,Throat 
 n/a  n/a  n/a  n/a  n/a  n/a 
18 
Chronic Specialty: Unstable-
Eye 
0.42 0.41 0.17 0.15 0.06 0.09 
20 Dermatologic 0.40 0.32 0.31 0.24 0.47 0.54 
21 
Injuries/Adverse Effects: 
Minor 
2.94 3.10 6.33 5.51 1.11 1.65 
22 
Injuries/Adverse Effects: 
Major 
3.54 3.46 8.89 7.74 2.52 2.86 
23 
Psychosocial: Time Limited, 
Minor 
0.01 0.01 0.02 0.04 0.06 0.04 
24 
Psychosocial:Recurrent or 
Persistent,Stable 
0.27 0.36 0.03 0.03 0.24 0.26 
25 
Psychosocial:Recurrent or 
Persistent,Unstable 
0.03 0.03 0.04 0.04 0.10 0.12 
26 Signs/Symptoms: Minor 2.86 2.87 1.19 1.38 1.65 1.47 
27 Signs/Symptoms: Uncertain 5.62 5.71 5.51 4.66 5.14 5.33 
28 Signs/Symptoms: Major 3.17 2.88 3.78 3.84 3.81 5.40 
29 Discretionary 5.23 4.62 7.36 6.95 21.57 21.92 
30 See and Reassure 0.07 0.15 0.24 0.22 0.08 0.11 
31 Prevention/Administrative 3.99 4.45 3.35 4.24 10.11 7.78 
32 Malignancy 1.98 3.12 2.73 2.61 7.36 8.39 
33 Pregnancy 6.86 6.12 12.42 12.74 0.02 0.06 
34 Dental 0.01 0.00 0.02 0.05 0.01 0.01 
 
Total Number of ADGs 40,605 43,669 29,674 31,981 14,121 17,034 
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 Figure 3.6 ADGs Distributions of Hospital A (HA) in Two Years presented the 
distributions of ADGs for the hospitals A (HA) in 2010 and 2011.  In total, 40,605 ADGs 
and 43,669 ADGs were generated from the populations from the hospital A in 2010 and 
2011 respectively. ADG 11, Chronic Medical: Unstable, was the most frequent ADG 
both 2010 and 2011. ADG 34, Dental, and ADG 23, Psychosocial: Time Limited, Minor, 
were the least frequent ADGs in 2010 with approximately the same frequency. ADG 34, 
Dental, was the least frequent ADGs in 2011 with a value close to 0. ADG 5, Allergies, 
was not observed in 2010 and its frequency was very limited in 2011.  
Figure 3.6 ADGs Distributions of Hospital A (HA) in Two Years 
 
 Figure 3.7 presented the distributions of ADGs for the hospital B (HB) in 2010 
and 2011. Totally, 29,674 ADGs and 31,981 ADGs were generated from the populations 
from the hospital B (HB) in 2010 and 2011 respectively. ADG 33, Pregnancy, was the 
most frequent ADG both in 2010 and 2011 for the patient populations of the hospital B 
(HB). ADG 34, Dental, was the least frequent ADG in 2010 and ADG 5, Allergies, was 
the least ADG in 2011 with a value close to 0 and it was not observed in 2010.  
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Figure 3.7 ADGs Distributions of Hospital B (HB) in Two Years 
 
 Figure 3.8 presented the distributions of ADGs for the hospital C (HC) in 2010 
and 2011. In total, 14,121 ADGs and 17,034 ADGs were generated from the populations 
from hospital C in 2010 and 2011 respectively. ADG 29, Discretionary, and ADG 34, 
Dental, were the most and least frequent ADGs for the patient populations of the hospital 
C in both 2010 and 2011.  
Figure 3.8 ADGs Distributions of Hospital C (HC) in Two Years 
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3.4 ACG 
3.4.1 ACGs Distributions for Insurance Companies  
 The distributions of study populations according to the actuarial cells, known as 
the ACGs, for the specific insurance companies and years were summarized in Table 3.7. 
Out of the total 105 ACGs, 89 ACGs were observed in the population aggregated from 3 
insurance companies in 2010 and 2011. Compared with full ACGs categories, 16 ACGs 
categories were not observed in the aggregated population from the 3 insurance 
companies, most of which being related to pregnancy and infants. Table 3.8 listed all 
ACGs which were unseen in the aggregated population from the 3 insurance companies. 
None of the populations was classified into the ACG 5200, Non-Users. Only in the 
patient populations of the insurance company A, 89 observed ACGs were observed in the 
patient populations, whereas 58 and 88 ACGs were observed in the populations from the 
insurance companies B and C respectively.  
 Comparing the population frequency distributions according to ACGs among the 
3 insurance companies in 2010 and 2011, most of the ACGs showed similar population 
frequency distributions. However, the frequency distributions of some ACGs varied 
modestly across different companies or years. Some of the observed ACGs were only 
from one or two insurance companies, leaving these ACGs unobserved in the populations 
of the other companies during the analysis at the company level. No more than 1.67% of 
the population of the insurance companies were classified into ACG 5110, No Diagnosis 
or Only Unclassified Diagnosis (2 input files).   
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Table 3.7 ACGs Distributions of Specific Insurance Companies according to Years 
(Unit: Percentage in Population) 
ACG 
Number 
ACG Description 
2010 
IA 
2011 
IA 
2010  
IB 
2011  
IB 
2010 
IC 
2011 
IC 
0100 Acute Minor, Age 1 1.078 1.310 0.033 1.673 0.100 1.003 
0200 Acute Minor, Age 2 to 5 4.026 4.492 5.816 8.421 0.564 3.108 
0300 Acute Minor, Age > 5 26.395 24.977 36.823 34.126 15.008 20.876 
0400 Acute Major 11.392 6.338 9.239 9.126 11.417 11.357 
0500 Likely to Recur, w/o Allergies 7.909 7.036 8.475 7.629 4.998 4.241 
0600 Likely to Recur, with Allergies 0.717 0.670 0.665 0.469 0.085 0.390 
0700 Asthma 0.277 0.219 0.233 0.411 0.162 0.082 
0800 Chronic Medical, Unstable 1.333 0.787 0.964 0.822 15.379 0.969 
0900 Chronic Medical, Stable 4.524 3.091 2.725 2.113 10.258 1.730 
1000 Chronic Specialty, Stable 0.353 0.166 0.233 0.293 0.888 0.259 
1100 Eye/Dental 4.030 3.464 2.725 3.052 1.475 2.093 
1200 Chronic Specialty, Unstable 0.083 0.081 0.066 0.117 0.124 0.057 
1300 Psychosocial, w/o Psych Unstable 0.238 0.189 0.033 0.029 0.062 0.258 
1400 
Psychosocial, with Psych 
Unstable, w/o Psych Stable 
0.030 0.034  n/a  n/a 0.070 0.009 
1500 
Psychosocial, with Psych 
Unstable, w/ Psych Stable 
 n/a 0.001  n/a  n/a 0.008 0.001 
1600 Preventive/Administrative 6.219 3.335 0.166 0.352 2.441 8.697 
1711 Pregnancy: 0-1 ADGs, delivered 0.744 0.503   0.059 0.216 0.407 
1712 
Pregnancy: 0-1 ADGs, not 
delivered 
0.570 0.434 0.133 0.088 0.093 0.279 
1721 
Pregnancy: 2-3 ADGs, no Major 
ADGs, delivered 
0.307 0.392 0.066 0.029  n/a 0.202 
1722 
Pregnancy: 2-3 ADGs, no Major 
ADGs, not delivered 
0.264 0.534 0.133 0.117 0.100 0.360 
1731 
Pregnancy: 2-3 ADGs, 1+ Major 
ADGs, delivered 
0.021 0.023  n/a  n/a  n/a 0.029 
1732 
Pregnancy: 2-3 ADGs, 1+ Major 
ADGs, not delivered 
0.053 0.080  n/a  n/a 0.008 0.055 
1741 
Pregnancy: 4-5 ADGs, no Major 
ADGs, delivered 
0.062 0.093  n/a  n/a  n/a 0.054 
1742 
Pregnancy: 4-5 ADGs, no Major 
ADGs, not delivered 
0.081 0.186  n/a 0.059 0.015 0.160 
1751 
Pregnancy: 4-5 ADGs, 1+ Major 
ADGs, delivered 
0.017 0.035  n/a  n/a  n/a 0.013 
1752 
Pregnancy: 4-5 ADGs, 1+ Major 
ADGs, not delivered 
0.032 0.068 0.033  n/a 0.008 0.051 
1761 
Pregnancy: 6+ ADGs, no Major 
ADGs, delivered 
0.029 0.032  n/a  n/a  n/a 0.017 
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1762 
Pregnancy: 6+ ADGs, no Major 
ADGs, not delivered 
0.029 0.048  n/a  n/a 0.008 0.058 
1771 
Pregnancy: 6+ ADGs, 1+ Major 
ADGs, delivered 
0.028 0.031  n/a  n/a  n/a 0.013 
1772 
Pregnancy: 6+ ADGs, 1+ Major 
ADGs, not delivered 
0.038 0.063  n/a  n/a 0.015 0.039 
1800 Acute Minor and Acute Major 4.487 5.492 7.810 6.191 2.564 6.384 
1900 
Acute Minor and Likely to Recur, 
Age 1 
0.078 0.200  n/a 0.059 0.023 0.194 
2000 
Acute Minor and Likely to Recur, 
Age 2 to 5 
0.310 0.711 0.631 0.792 0.062 0.644 
2100 
Acute Minor and Likely to Recur, 
Age > 5, w/o Allergy 
2.619 5.823 5.616 6.250 1.576 4.317 
2200 
Acute Minor and Likely to Recur, 
Age > 5, with Allergy 
0.226 0.728 0.432 0.323 0.093 0.564 
2300 
Acute Minor and Chronic 
Medical: Stable 
1.890 2.580 1.263 1.496 1.074 1.335 
2400 Acute Minor and Eye/Dental 1.342 2.552 2.027 2.523 0.502 2.211 
2500 
Acute Minor and Psychosocial, 
w/o Psych Unstable 
0.096 0.174  n/a 0.059 0.077 0.215 
2600 
Acute Minor and Psychosocial, 
with Psych Unstable, w/o Psych 
Stable 
0.015 0.027  n/a  n/a 0.008 0.008 
2700 
Acute Minor and Psychosocial, 
with Psych Unstable and Psych 
Stable 
 n/a 0.001  n/a  n/a  n/a 0.001 
2800 Acute Minor and Likely to Recur 1.138 1.498 1.994 1.555 1.058 1.484 
2900 
Acute Minor/Acute Major/Likely 
to Recur, Age 1 
0.037 0.047  n/a  n/a  n/a 0.094 
3000 
Acute Minor/Acute Major/Likely 
to Recur, Age 2 to 5 
0.148 0.177 0.133 0.059  n/a 0.352 
3100 
Acute Minor/Acute Major/Likely 
to Recur, Age 6 to 11 
0.066 0.083 0.033 0.029 0.008 0.133 
3200 
Acute Minor/Acute Major/Likely 
to Recur, Age > 11, w/o Allergy 
1.317 2.266 2.227 1.995 1.398 2.894 
3300 
Acute Minor/Acute Major/Likely 
to Recur, Age > 11, with Allergy 
0.124 0.223 0.133 0.147 0.131 0.305 
3400 
Acute Minor/Likely to Recur/Eye 
& Dental 
0.389 1.049 0.532 0.558 0.139 0.921 
3500 
Acute Minor/Likely to 
Recur/Psychosocial 
0.033 0.095  n/a  n/a 0.031 0.117 
3600 
Acute Minor/Acute Major/Likely 
Recur/Eye & Dental 
0.700 0.857 0.266 0.411 1.305 1.052 
3700 
Acute Minor/Acute Major/Likely 
Recur/Psychosocial 
0.039 0.055  n/a  n/a 0.093 0.134 
3800 
2-3 Other ADG Combinations, 
Age < 18 
0.871 0.988 0.465 0.411 0.070 0.605 
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3900 
2-3 Other ADG Combinations, 
Males Age 18 to 34 
1.067 1.557 1.230 0.734 0.564 1.259 
4000 
2-3 Other ADG Combinations, 
Females Age 18 to 34 
1.638 2.516 1.695 1.966 0.742 1.732 
4100 
2-3 Other ADG Combinations, 
Age > 34 
2.681 2.738 2.625 2.582 8.891 3.379 
4210 
4-5 Other ADG Combinations, 
Age < 18, no Major ADGs 
0.301 0.403 0.033 0.088 0.031 0.481 
4220 
4-5 Other ADG Combinations, 
Age < 18, 1+ Major ADGs 
0.168 0.163 0.033 0.029 0.015 0.125 
4310 
4-5 Other ADG Combinations, 
Age 18 to 44, no Major ADGs 
1.168 1.886 0.499 1.115 0.757 2.239 
4320 
4-5 Other ADG Combinations, 
Age 18 to 44, 1+ Major ADGs 
0.667 1.133 0.299 0.558 0.904 1.000 
4330 
4-5 Other ADG Combinations, 
Age 18 to 44, 2+ Major ADGs 
0.094 0.203 0.066 0.088 0.100 0.137 
4410 
4-5 Other ADG Combinations, 
Age > 44, no Major ADGs 
0.433 0.281 0.233 0.059 1.228 0.779 
4420 
4-5 Other ADG Combinations, 
Age > 44, 1+ Major ADGs 
0.266 0.177 0.133 0.147 4.210 0.817 
4430 
4-5 Other ADG Combinations, 
Age > 44, 2+ Major ADGs 
0.035 0.038  n/a 0.059 1.027 0.163 
4510 
6-9 Other ADG Combinations, 
Age < 6, no Major ADGs 
0.064 0.067  n/a  n/a  n/a 0.084 
4520 
6-9 Other ADG Combinations, 
Age < 6, 1+ Major ADGs 
0.083 0.058 0.033  n/a 0.008 0.038 
4610 
6-9 Other ADG Combinations, 
Age 6 to 17, no Major ADGs 
0.014 0.021  n/a  n/a  n/a 0.055 
4620 
6-9 Other ADG Combinations, 
Age 6 to 17, 1+ Major ADGs 
0.014 0.017  n/a  n/a  n/a 0.019 
4710 
6-9 Other ADG Combinations, 
Males, Age 18 to 34, no Major 
ADGs 
0.090 0.116 0.100 0.029 0.015 0.143 
4720 
6-9 Other ADG Combinations, 
Males, Age 18 to 34, 1+ Major 
ADGs 
0.091 0.106 0.033 0.029 0.077 0.095 
4730 
6-9 Other ADG Combinations, 
Males, Age 18 to 34, 2+ Major 
ADGs 
0.036 0.035  n/a 0.029 0.046 0.029 
4810 
6-9 Other ADG Combinations, 
Females, Age 18 to 34, no Major 
ADGs 
0.167 0.239  n/a 0.088 0.062 0.358 
4820 
6-9 Other ADG Combinations, 
Females, Age 18 to 34, 1+ Major 
ADGs 
0.196 0.220 0.133 0.059 0.054 0.253 
4830 
6-9 Other ADG Combinations, 
Females, Age 18 to 34, 2+ Major 
ADGs 
0.051 0.090 0.100 0.088 0.039 0.053 
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Table 3.8 List of Absent ACGs for All Insurance Companies 
ACG Number Descriptions 
 1710 Pregnancy, 0-1 ADGs 
 1720 Pregnancy, 2-3 ADGs, no Major ADGs 
 1730 Pregnancy, 2-3 ADGs, 1+Major ADGs 
 1740 Pregnancy, 4-5 ADGs, no Major ADGs 
 1750 Pregnancy, 4-5 ADGs, 1+Major ADGs 
 1760 Pregnancy, 6+ ADGs, no Major ADGs 
 1770 Pregnancy, 6+ ADGs, 1+ Major ADGs 
4910 
6-9 Other ADG Combinations, 
Age > 34, 0-1 Major ADGs 
0.331 0.380 0.066 0.176 4.287 1.754 
4920 
6-9 Other ADG Combinations, 
Age > 34, 2 Major ADGs 
0.056 0.074 0.133  n/a 1.977 0.423 
4930 
6-9 Other ADG Combinations, 
Age > 34, 3 Major ADGs 
0.006 0.014 0.033  n/a 0.332 0.055 
4940 
6-9 Other ADG Combinations, 
Age > 34, 4+ Major ADGs 
 n/a 0.001  n/a  n/a 0.015 0.003 
5010 
10+ Other ADG Combinations, 
Age 1 to 17, no Major ADGs 
0.002 0.002  n/a  n/a  n/a 0.001 
5020 
10+ Other ADG Combinations, 
Age 1 to 17, 1 Major ADGs 
0.005 0.005  n/a  n/a  n/a 0.001 
5030 
10+ Other ADG Combinations, 
Age 1 to 17, 2 Major ADGs 
0.003 0.001  n/a  n/a  n/a n/a 
5040 
10+ Other ADG Combinations, 
Age > 17, 0-1 Major ADGs 
0.022 0.030  n/a  n/a 0.062 0.116 
5050 
10+ Other ADG Combinations, 
Age > 17, 2 Major ADGs 
0.020 0.016  n/a  n/a 0.162 0.084 
5060 
10+ Other ADG Combinations, 
Age > 17, 3 Major ADGs 
0.006 0.008  n/a  n/a 0.062 0.028 
5070 
10+ Other ADG Combinations, 
Age > 17, 4+ Major ADGs 
 n/a 0.001  n/a  n/a n/a 0.007 
5110 
No Diagnosis or Only 
Unclassified Diagnosis (2 input 
files) 
1.666 1.670 0.399 0.235 0.371 1.073 
5311 
Infants: 0-5 ADGs, no Major 
ADGs, low birth weight 
 n/a 0.000  n/a  n/a  n/a 0.001 
5312 
Infants: 0-5 ADGs, no Major 
ADGs, normal birth weight 
1.625 1.302  n/a  n/a 0.247 2.269 
5322 
Infants: 0-5 ADGs, 1+ Major 
ADGs, normal birth weight 
0.102 0.082  n/a  n/a  n/a 0.073 
5332 
Infants: 6+ ADGs, no Major 
ADGs, normal birth weight 
0.014 0.002  n/a  n/a  n/a 0.032 
5342 
Infants: 6+ ADGs, 1+ Major 
ADGs, normal birth weight 
0.012 0.007  n/a  n/a  n/a 0.011 
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 5200 Non-Users (two input files), 
 5310 Infants: 0-5 ADGs, no Major ADGs 
 5320 Infants: 0-5 ADGs, 1+Major ADGs 
 5321 Infants: 0-5 ADGs, 1+Major ADGs, Low  Birth Weight 
 5330 Infants: 6+ ADGs, no Major ADGs 
 5331 Infants: 6+ ADGs, no Major ADGs, Low Birth Weight 
 5340 Infants: 6+ ADGs, 1+ Major ADGs 
 5341 Infants: 6+ ADGs, 1+ Major ADGs, Low Birth Weight 
 9900 Invalid Age or Date of Birth 
 
 At the analysis of the aggregated population of all insurance companies, ACG 
0300, Acute Minor, Age > 5, was the most frequent ACG category for all the 3 insurance 
companies in two years, accounting for 15%-37% of the populations depending on the 
company and the year. However, the least frequent ACG category varied across the 3 
insurance companies and years.  
 For insurance company A (IA), 89 ACGs categories were observed in both 2010 
and 2011. The least frequent ACGs for insurance company A were ACG 5010 (10+ 
Other ADG Combinations, Age 1 to 17, no Major ADGs) and ACG 5311 (10+ Other 
ADG Combinations, Age 1 to 17, no Major ADGs) for year 2010 and 2011 respectively.  
Overall, the distributions of the ACGs showed similar patterns over the two years for the 
populations from the insurance company A. The frequencies of the ACG 0400 (Acute 
Major) and the ACG 1600 (Preventive/Administrative), decreased significantly from 
2010 to 2011. In contrast, the frequency of the ACG 2100 increased significantly from 
2010 to 2011. In both 2010 and 2011, the distribution of the ACGs was concentrated 
among a few ACGs, such as ACG 0200, ACG 0300, ACG 0400, ACG 0500, ACG 0900, 
ACG 1100, ACG 1600, ACG 1800, and ACG 2100.  
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 For insurance company B (IB), 58 ACGs categories were observed in two years, 
resulting in 47 possible ACGs categories absent from the populations. Compared with all 
possible ACGs, the absent ACGs of the patient populations from insurance company B 
was summarized in Table 3.9. Some of the 58 ACGs were only observed in one year’s 
data. ACG 1752, ACG 4520, ACG 4920, and ACG 4930 were only observed in 2010.  
ACG 1711, ACG 1742, ACG 1900, ACG 2500, ACG 4430, ACG 4730, and ACG 4810 
were only observed in 2011. Of those ACGs which were only observed in one year’s data, 
no more than 0.2% of the populations were classified into any of those ACGs. The least 
frequent ACGs for insurance company B were ACG 0100 (Acute Minor, Age 1) and 
ACG 1300 (Psychosocial, w/o Psych Unstable) for the years 2010 and 2011 respectively.  
Overall, the distributions of the ACGs showed very similar patterns over the two years 
for the patient populations of insurance company B as well. The frequency of ACG 0100 
was increased significantly from 2010 to 2011. However, its frequency still remained low 
in 2011. In both 2010 and 2011, the distribution of the ACGs was concentrated among a 
few ACGs, including ACG 0200, ACG 0300, ACG 0400, ACG 0500, ACG 1800, and 
ACG 2100.  
Table 3.9 List of Absent ACGs for Insurance Company B in Two Years 
ACG Number ACG Description 
1400 Psychosocial, with Psych Unstable, w/o Psych Stable 
1500 Psychosocial, with Psych Unstable, w/ Psych Stable 
1731 Pregnancy: 2-3 ADGs, 1+ Major ADGs, delivered 
1732 Pregnancy: 2-3 ADGs, 1+ Major ADGs, not delivered 
1741 Pregnancy: 4-5 ADGs, no Major ADGs, delivered 
1751 Pregnancy: 4-5 ADGs, 1+ Major ADGs, delivered 
1761 Pregnancy: 6+ ADGs, no Major ADGs, delivered 
1762 Pregnancy: 6+ ADGs, no Major ADGs, not delivered 
1771 Pregnancy: 6+ ADGs, 1+ Major ADGs, delivered 
1772 Pregnancy: 6+ ADGs, 1+ Major ADGs, not delivered 
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2600 Acute Minor and Psychosocial, with Psych Unstable, w/o Psych Stable 
2700 Acute Minor and Psychosocial, with Psych Unstable and Psych Stable 
2900 Acute Minor/Acute Major/Likely to Recur, Age 1 
3500 Acute Minor/Likely to Recur/Psychosocial 
3700 Acute Minor/Acute Major/Likely Recur/Psychosocial 
4510 6-9 Other ADG Combinations, Age < 6, no Major ADGs 
4610 6-9 Other ADG Combinations, Age 6 to 17, no Major ADGs 
4620 6-9 Other ADG Combinations, Age 6 to 17, 1+ Major ADGs 
4940 6-9 Other ADG Combinations, Age > 34, 4+ Major ADGs 
5010 10+ Other ADG Combinations, Age 1 to 17, no Major ADGs 
5020 10+ Other ADG Combinations, Age 1 to 17, 1 Major ADGs 
5030 10+ Other ADG Combinations, Age 1 to 17, 2 Major ADGs 
5040 10+ Other ADG Combinations, Age > 17, 0-1 Major ADGs 
5050 10+ Other ADG Combinations, Age > 17, 2 Major ADGs 
5060 10+ Other ADG Combinations, Age > 17, 3 Major ADGs 
5070 10+ Other ADG Combinations, Age > 17, 4+ Major ADGs 
5311 Infants: 0-5 ADGs, no Major ADGs, low birth weight 
5312 Infants: 0-5 ADGs, no Major ADGs, normal birth weight 
5322 Infants: 0-5 ADGs, 1+ Major ADGs, normal birth weight 
5332 Infants: 6+ ADGs, no Major ADGs, normal birth weight 
5342 Infants: 6+ ADGs, 1+ Major ADGs, normal birth weight 
  
 For insurance company C, 88 ACGs categories were observed in both 2010 and 
2011. In 2010, the least frequent ACGs for insurance company C consisted of a group of 
7 ACGs whose frequencies were the same that only had few patients in each group. 
These ACGs were ACG 1500, ACG 1732, ACG 1752, ACG 1762, ACG 2600, ACG 
3100, and ACG 4520. Similarly, in 2011, the least frequent ACGs for insurance company 
C consisted of a group of 5 ACGs whose frequencies were the same. These ACGs were 
ACG 1500, ACG 2700, ACG 5010, ACG 5020, and ACG 5311. Overall, the distributions 
of the ACGs varied moderately for the populations of insurance company C between 
2010 and 2011. The frequencies of the ACG 0800, ACG 0900, ACG 4100, ACG 4420, 
and the ACG 4910 were decreased significantly from 2010 to 2011. In contrast, the 
frequency of ACG 0300, ACG 1600 and ACG 1800 increased significantly from 2010 to 
2011. The ACGs group in which patients were highly concentrated varied between 2010 
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and 2011. In 2010, the distribution of ACGs was concentrated among a few ACGs, such 
as ACG 0300, ACG 0400, ACG 0500, ACG 0800, ACG 0900, ACG 4100, ACG 4420, 
and ACG 4910. In 2111, the distribution of the ACGs was not only concentrated among a 
few of the ACGs which were present in 2010, such as ACG 0300, ACG 0400, and ACG 
0500, but among a few new ACGs such as ACG 0200, ACG1600, ACG 1800, and ACG 
2100.  
3.4.2 ACGs Distributions for Hospitals  
 The distributions of inpatient populations according to the ACGs for specific 
hospitals and years were summarized in Table 3.10. Out of the complete 105 ACGs, 39 
ACGs in total were observed in the population aggregated from 3 hospitals in 2010 and 
2011. Compared with the full set of ACGs categories, 66 ACGs categories were not 
observed in the aggregated population from the 3 hospitals. Table 3.11 listed all ACGs 
which were unseen in the aggregated population from the 3 hospitals. None of the 
populations was classified into the ACG 5200, Non-Users.  
Table 3.10 ACGs Distributions of Specific Hospitals according to Years (Unit: 
Percentage in Population) 
ACG 
Number 
ACG Description 
2010 
HA 
2011 
HA  
2010 
HB  
2011 
HB  
2010 
HC  
2011 
HC  
0100 Acute Minor, Age 1 2.785 2.584 0.226 3.163 n/a n/a 
0200 Acute Minor, Age 2 to 5 4.301 4.053 6.362 4.568 0.028 0.049 
0300 Acute Minor, Age > 5 12.575 12.071 11.023 10.571 7.674 7.778 
0400 Acute Major 19.316 18.458 26.531 24.822 17.928 19.644 
0500 Likely to Recur, w/o Allergies 8.529 7.795 10.202 9.476 31.454 31.764 
0600 Likely to Recur, with Allergies 0.000 0.007 n/a 0.003 0.042 0.030 
0700 Asthma 0.193 0.162 0.800 0.860 0.212 0.243 
0800 Chronic Medical, Unstable 23.753 27.287 17.830 17.347 21.271 21.730 
0900 Chronic Medical, Stable 7.215 7.797 8.756 9.733 8.876 7.967 
1000 Chronic Specialty, Stable 0.725 0.955 0.711 0.650 1.215 1.101 
1100 Eye/Dental 1.123 1.104 0.424 0.441 0.346 0.772 
1200 Chronic Specialty, Unstable 0.615 0.500 0.178 0.187 0.184 0.195 
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1300 Psychosocial, w/o Psych Unstable 0.262 0.351 0.051 0.073 0.297 0.262 
1400 
Psychosocial, with Psych Unstable, 
w/o Psych Stable 
0.031 0.027 0.038 0.041 0.099 0.109 
1600 Preventive/Administrative 3.522 3.652 2.832 3.766 10.112 6.361 
1711 Pregnancy: 0-1 ADGs, delivered 6.700 5.927 5.883 3.284 n/a n/a 
1712 
Pregnancy: 0-1 ADGs, not 
delivered 
0.131 0.171 6.567 9.565 0.035 0.055 
1721 
Pregnancy: 2-3 ADGs, no Major 
ADGs, delivered 
0.019 0.016 0.017 0.010 n/a n/a 
1722 
Pregnancy: 2-3 ADGs, no Major 
ADGs, not delivered 
n/a n/a 0.048 0.044 n/a n/a 
1731 
Pregnancy: 2-3 ADGs, 1+ Major 
ADGs, delivered 
0.005 0.007 0.003 n/a n/a n/a 
1732 
Pregnancy: 2-3 ADGs, 1+ Major 
ADGs, not delivered 
n/a n/a 0.003 0.029 n/a 0.012 
1800 Acute Minor and Acute Major 0.069 0.088 0.123 0.136 n/a 0.116 
1900 
Acute Minor and Likely to Recur, 
Age 1 
n/a n/a n/a 0.003 n/a n/a 
2000 
Acute Minor and Likely to Recur, 
Age 2 to 5 
0.002 0.005 0.007 0.006 n/a n/a 
2100 
Acute Minor and Likely to Recur, 
Age > 5, w/o Allergy 
0.038 0.052 0.041 0.010 n/a 0.061 
2300 
Acute Minor and Chronic Medical: 
Stable 
0.029 0.041 0.048 0.051 n/a 0.079 
2400 Acute Minor and Eye/Dental 0.007 0.002 n/a 0.003 n/a 0.003 
2500 
Acute Minor and Psychosocial, w/o 
Psych Unstable 
0.002 0.002 n/a n/a n/a 0.006 
2800 Acute Minor and Likely to Recur 0.114 0.101 0.096 0.067 n/a 0.170 
2900 
Acute Minor/Acute Major/Likely to 
Recur, Age 1 
n/a n/a n/a 0.003 n/a n/a 
3800 
2-3 Other ADG Combinations, Age 
< 18 
0.033 0.027 0.021 0.032 n/a 0.006 
3900 
2-3 Other ADG Combinations, 
Males Age 18 to 34 
0.010 0.011 n/a 0.019 n/a 0.024 
4000 
2-3 Other ADG Combinations, 
Females Age 18 to 34 
0.024 0.014 0.007 0.010 n/a 0.036 
4100 
2-3 Other ADG Combinations, 
Age > 34 
1.030 1.212 0.691 0.660 n/a 1.356 
4420 
4-5 Other ADG Combinations, 
Age > 44, 1+ Major ADGs 
0.002 0.000 0.002 0.000 n/a n/a 
4430 
4-5 Other ADG Combinations, 
Age > 44, 2+ Major ADGs 
0.002 0.005 n/a n/a n/a n/a 
5110 
No Diagnosis or Only Unclassified 
Diagnosis (2 input files) 
5.477 4.445 0.482 0.368 0.219 0.061 
5312 
Infants: 0-5 ADGs, no Major 
ADGs, normal birth weight 
1.323 1.043 n/a n/a 0.007 0.006 
5322 
Infants: 0-5 ADGs, 1+ Major 
ADGs, normal birth weight 
0.036 0.027 n/a n/a n/a 0.006 
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Table 3.11 List of Absent ACGs for the Populations from All Hospitals 
ACG Number Description 
1500 Psychosocial, with Psych Unstable, w/ Psych Stable 
1710 Pregnancy, 0-1 ADGs 
1720 Pregnancy, 2-3 ADGs, no Major ADGs 
1730 Pregnancy, 2-3 ADGs, 1+Major ADGs 
1740 Pregnancy, 4-5 ADGs, no Major ADGs 
1741 Pregnancy: 4-5 ADGs, no Major ADGs, delivered 
1742 Pregnancy: 4-5 ADGs, no Major ADGs, not delivered 
1750 Pregnancy, 4-5 ADGs, 1+Major ADGs 
1751 Pregnancy: 4-5 ADGs, 1+ Major ADGs, delivered 
1752 Pregnancy: 4-5 ADGs, 1+ Major ADGs, not delivered 
1760 Pregnancy, 6+ ADGs, no Major ADGs 
1761 Pregnancy: 6+ ADGs, no Major ADGs, delivered 
1762 Pregnancy: 6+ ADGs, no Major ADGs, not delivered 
1770 Pregnancy, 6+ ADGs, 1+ Major ADGs 
1771 Pregnancy: 6+ ADGs, 1+ Major ADGs, delivered 
1772 Pregnancy: 6+ ADGs, 1+ Major ADGs, not delivered 
2200 Acute Minor and Likely to Recur, Age > 5, with Allergy 
2600 Acute Minor and Psychosocial, with Psych Unstable, w/o Psych Stable 
2700 Acute Minor and Psychosocial, with Psych Unstable and Psych Stable 
3000 Acute Minor/Acute Major/Likely to Recur, Age 2 to 5 
3100 Acute Minor/Acute Major/Likely to Recur, Age 6 to 11 
3200 Acute Minor/Acute Major/Likely to Recur, Age > 11, w/o Allergy 
3300 Acute Minor/Acute Major/Likely to Recur, Age > 11, with Allergy 
3400 Acute Minor/Likely to Recur/Eye & Dental 
3500 Acute Minor/Likely to Recur/Psychosocial 
3600 Acute Minor/Acute Major/Likely Recur/Eye & Dental 
3700 Acute Minor/Acute Major/Likely Recur/Psychosocial 
4210 4-5 Other ADG Combinations, Age < 18, no Major ADGs 
4220 4-5 Other ADG Combinations, Age < 18, 1+ Major ADGs 
4310 4-5 Other ADG Combinations, Age 18 to 44, no Major ADGs 
4320 4-5 Other ADG Combinations, Age 18 to 44, 1+ Major ADGs 
4330 4-5 Other ADG Combinations, Age 18 to 44, 2+ Major ADGs 
4410 4-5 Other ADG Combinations, Age > 44, no Major ADGs 
4510 6-9 Other ADG Combinations, Age < 6, no Major ADGs 
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4520 6-9 Other ADG Combinations, Age < 6, 1+ Major ADGs 
4610 6-9 Other ADG Combinations, Age 6 to 17, no Major ADGs 
4620 6-9 Other ADG Combinations, Age 6 to 17, 1+ Major ADGs 
4710 6-9 Other ADG Combinations, Males, Age 18 to 34, no Major ADGs 
4720 6-9 Other ADG Combinations, Males, Age 18 to 34, 1+ Major ADGs 
4730 6-9 Other ADG Combinations, Males, Age 18 to 34, 2+ Major ADGs 
4810 6-9 Other ADG Combinations, Females, Age 18 to 34, no Major ADGs 
4820 6-9 Other ADG Combinations, Females, Age 18 to 34, 1+ Major ADGs 
4830 6-9 Other ADG Combinations, Females, Age 18 to 34, 2+ Major ADGs 
4910 6-9 Other ADG Combinations, Age > 34, 0-1 Major ADGs 
4920 6-9 Other ADG Combinations, Age > 34, 2 Major ADGs 
4930 6-9 Other ADG Combinations, Age > 34, 3 Major ADGs 
4940 6-9 Other ADG Combinations, Age > 34, 4+ Major ADGs 
5010 10+ Other ADG Combinations, Age 1 to 17, no Major ADGs 
5020 10+ Other ADG Combinations, Age 1 to 17, 1 Major ADGs 
5030 10+ Other ADG Combinations, Age 1 to 17, 2 Major ADGs 
5040 10+ Other ADG Combinations, Age > 17, 0-1 Major ADGs 
5050 10+ Other ADG Combinations, Age > 17, 2 Major ADGs 
5060 10+ Other ADG Combinations, Age > 17, 3 Major ADGs 
5070 10+ Other ADG Combinations, Age > 17, 4+ Major ADGs 
5310 Infants: 0-5 ADGs, no Major ADGs 
5200 Non-Users (two input files), 
5311 Infants: 0-5 ADGs, no Major ADGs, low birth weight 
5320 Infants: 0-5 ADGs, 1+Major ADGs 
5321 Infants: 0-5 ADGs, 1+Major ADGs, Low  Birth Weight 
5322 Infants: 0-5 ADGs, 1+ Major ADGs, normal birth weight 
5330 Infants: 6+ ADGs, no Major ADGs 
5331 Infants: 6+ ADGs, no Major ADGs, Low Birth Weight 
5340 Infants: 6+ ADGs, 1+ Major ADGs 
5341 Infants: 6+ ADGs, 1+ Major ADGs, Low Birth Weight 
5342 Infants: 6+ ADGs, 1+ Major ADGs, normal birth weight 
9900 Invalid Age or Date of Birth 
 
 At the specific hospital level of analysis, both the most and the least frequent 
ACG categories varied across hospitals and years. The distributions of the ACGs in two 
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consecutive years were similar within a hospital but slightly different among different 
hospitals.       
  For hospital A (HA), in total, 35 ACGs were observed from the inpatient 
populations in two consecutive years. Among the total 39 ACGs which were observed in 
the aggregated populations from 3 hospitals, ACG 1722, ACG 1732, ACG 1900 and 
ACG 2900 were not observed in the populations from hospital A in neither 2010 nor 
2011. Both in 2010 and 2011, the most frequent ACG was ACG 0800. The least frequent 
ACGs were ACG 0600 and ACG 4420 for the years 2010 and 2011 respectively. The 
ACGs distributions in two consecutive years (2010, 2011) showed a very similar pattern. 
In both 2010 and 2011, the distribution of the ACGs was concentrated among ACG 0300, 
ACG 0400, ACG 0500, ACG 0800, ACG 0900, ACG 1711 and ACG 5110.  
  For hospital B (HB), 35 ACGs were observed from the inpatient populations in 
two consecutive years. Among the total 39 ACGs which were observed in the aggregated 
populations from 3 hospitals, ACG 2500, ACG 4430, ACG 5312, and ACG 5322 were 
not observed in the populations of hospital B in neither 2010 nor 2011. ACG 0600, ACG 
1900, and ACG 2400, ACG 2900, and ACG 3900 were not observed in the patient 
populations of hospital B only in the year 2011. Both in 2010 and 2011, the most and the 
least frequent ACGs were ACG 0400 and ACG 4420 respectively. The ACGs 
distributions in two consecutive years (2010, 2011) for hospital B also showed a very 
similar pattern. Both in 2010 and 2011, the distribution of the ACGs was concentrated 
among ACG 0200, ACG 0300, ACG 0400, ACG 0500, ACG 0800, ACG 0900, ACG 
1711 and ACG 1712. 
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 For the hospital C (HC), 29 ACGs were observed from the inpatient populations 
in two consecutive years. Among the total 39 ACGs, which were observed in the 
aggregated population from 3 hospitals, ACG 0100, ACG 1711, ACG 1721, ACG 1722, 
ACG 1731, ACG 1900, ACG 2000, ACG 2900, ACG 4420, and ACG 4430 were not 
observed in the populations of hospital C in neither 2010 nor 2011. ACG 1732, ACG 
1800, ACG 2100, ACG 2300, ACG 2400, ACG 2500, ACG 2800, ACG 3800, ACG 
3900, ACG 4000, ACG 4100, ACG 5322 were not observed in the inpatient populations 
of hospital C only in the year 2010. Both in 2010 and 2011, the most frequent ACGs 
category was ACG 0500. The least frequent ACGs category was ACG 5312 and ACG 
2400 for the years 2010 and 2011 respectively. The ACGs distributions in two 
consecutive years (2010, 2011) showed a very similar pattern. Both in 2010 and 2011, the 
distribution of the ACGs was concentrated among ACG 0300, ACG 0400, ACG 0500, 
ACG 0800, ACG 0900, and ACG 1600. 
3.5 Regression 
 Three multiple linear regression models were built to explain the observed 
variability in the total healthcare expenditures in a given year for the data from a specific 
source. The adjusted R-squared (R
2
) was used to measure the performance of each model 
for analyzing the variability. Table 3.12 summarized the adjusted R
2
 results of the three 
models for analyzing the healthcare expenditures of insurance companies according to 
the specific source and year. Three regression models presented similar patterns of the 
models’ performance for explaining the variability of the annual total healthcare 
expenditures of the populations from insurance companies in two consecutive years. 
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Model 1, which utilized only age and gender as the independent variables, did not explain 
more than 7% of the variance in the annual total healthcare expenditures of the 
populations of most of the insurance companies in 2010 and 2011 except that in 2010, 
model 1 explained 32.12% of the variance in the annual total healthcare expenditures of 
the population from insurance company C.   
 Model 2, which included the presence or absence of each of the 32 ADGs and 
demographics (age and gender) as the independent variables, was able to explain 24.80% 
to 40.63% of the variance in the annual total healthcare expenditures of the populations 
from insurance companies in 2010 and 2011, depending on the source and year of the 
data.   Model 3, which only used the presence of one of the exclusive ACGs actuarial 
cell as the independent variable for an individual, achieved explanatory power between 
18.20% and 32.14% of the variance in the annual total health expenditures of the 
populations from the insurance companies in 2010 and 2011, depending on the source 
and year of the data.  
Table 3.12 Concurrent Adjusted R-Squared (R
2
) of Different Risk Adjustment 
Models for Analyzing Total Health Expenditures by Insurance Companies and 
Years (Unit: In Percentage)  
         Source-Year  
Model 
IA-2010 IB-2010 IC-2010 IA-2011 IB-2011 IC-2011 
Model 1 (AGE/Gender) 2.75  0.06 32.12 1.68 0.09 6.78 
Model 2 (ADGs) 24.80 35.09 40.63 25.05 33.08 25.06 
Model 3 (ACGs) 20.46 32.14 21.76 21.45 29.30 18.20 
 
 Figure 3.9 compared the pattern of the explanatory power of various risk 
adjustment models across insurance companies and years. For the insurance populations, 
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in most cases, the demographic information itself (model 1) explained little variance of 
the annual total healthcare expenditures. The additional morbidity information to the 
demographics (model 2) markedly increased the regression model’s explanatory power, 
which was measured by the adjusted R
2
. In comparison with model 2, model 3 utilizing 
the exclusive ACGs actuarial cells as the only independent variables, resulted in a lower 
explanatory power of the regression model. However, the performance of model 3 was 
still significantly higher than the demographic model (model 1). 
Figure 3.9 Compare Adjusted R-Squared (R
2
) for Different Risk Adjustment 
Models by Insurance Companies and Years 
 
 However, for the data from inpatient populations of the three hospitals, these three 
regression models showed somewhat different patterns in the performance for explaining 
the variability of the annual total healthcare expenditures in two consecutive years. Table 
3.13 summarized the adjusted R
2
 results of three models for analyzing the total inpatient 
health expenditures of hospitals according to the specific source and year. Overall, for the 
inpatient populations, model 1 showed the varied explanatory power for inpatient health 
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expenditures, which ranged from 5% to 21%. In 2010 and 2011, model 1 explained about 
15%-21% of the variations for the inpatient healthcare expenditures for both hospital A 
and hospital B whereas it explained no more than 6% of the inpatient healthcare 
expenditures for hospital C. Specifically, Model 1 explained 15.06% and 17.35% of the 
variability of the inpatient expenditures for hospital A in 2010 and 2011 respectively. It 
also explained 20.59% and 18.17% of the inpatient expenditures of the patients from 
hospital B in 2010 and 2011 respectively. However, diverging from the results observed 
in hospital A and B, model 1, only explained 5.36% and 5.83% of the inpatient 
expenditures of hospital C in 2010 and 2011 respectively. The explanatory powers of the 
model in two consecutive years were similar for a specific hospital, but were different 
across different hospitals. 
Table 3.13 Concurrent Adjusted R-Squared (R
2
) of Different Risk Adjustment 
Models for Analyzing Total Health Expenditures Hospitals and Years (Unit: In 
Percentage)  
                  Source-Year 
Models  
HA-2010 HB-2010 HC-2010 HA-2011 HB-2011 HC-2011 
Model 1 (AGE/Gender) 15.06 20.59 5.36 17.35 18.17 5.83 
Model 2 (ADG Model) 28.36 28.69 20.41 30.09 27.71 23.71 
Model 3 (ACG Model) 16.84 20.63 23.00 16.35 18.38 13.98 
 
 For various inpatient populations, model 2 explained about 20% to 30% of the 
inpatient health expenditures. For the years 2010 and 2011, the values of the adjusted R
2
 
were 28.36% and 30.9% for hospital A, 28.69% and 27.71% for hospital B, and 20.41% 
and 23.71 for hospital C respectively. For each specific inpatient population, compared 
with model 1, the additional morbidity information also increased the explanatory power 
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of the regression model in both 2010 and 2011. This improvement of the explanatory 
power of the regression model for the inpatient expenditures was moderate for the patient 
population from hospital B, which was about an 8% increase, but it was significant for 
the populations from hospital A and hospital C, which were about 13% and 15% 
increases respectively. In two consecutive years, the explanatory power of the model 2 
was not only similar for a specific hospital, but also similar across various hospitals and 
years.  
 For different inpatient populations, model 3 explained about 14% to 23% of the 
inpatient health expenditures. For the year 2010 and year 2011, the values of the adjusted 
R
2
 were 16.84% and 16.35% for hospital A, 20.63 % and 18.38% for hospital B, and 
23.00% and 13.98% for hospital C respectively. For each specific inpatient population, 
compared with model 2, using the ACG actuarial cell in model 3 decreased the 
explanatory power of the regression model across all hospitals and years, except for the 
inpatient population in 2010 of hospital C. In both 2010 and 2011, in comparison with 
model 2, the decrease in explanatory power of the regression model 3 was more than 
10% % for the patient population from hospital A but less than 10% for the patient 
population from hospital B and hospital C respectively. However, model 3 was able to 
explain 2.59% more of the variability in the annual total inpatient health expenditures 
than model 2 for the inpatient population in 2010 of hospital C, whereas in 2011, its 
ability was decreased by 9.73%. In addition, except for the patient populations from 
hospital C, in most of the cases, comparing with model 1, the improvements of the 
explanatory power of model 3 were limited for the inpatient population of the hospital A 
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and hospital B. Figure 3.10 compared the pattern of the explanatory power of various risk 
adjustment models across hospitals companies and years. 
Figure 3.10 Compare Adjusted R-Squared (R
2
) for Different Risk Adjustment 
Models by Hospitals and Years 
 
3.6 Relative Risk and Risk Adjustment  
 Table 3.14 summarized the distributions of relative risk among all the observed 
ACG categories of insurance company A in 2010 and 2011. In addition, the associated 
percentages of each ACG category in the populations as well as the associated cost 
percentages of each of the ACGs in the total cost of insurance company A were listed in 
Table 3.14 according to years. Comparing the two years’ distributions of relative risk in 
Figure 3.11, most of the ACGs which existed in both two years showed similar 
distributions in 2010 and 2011. The ACG categories of the highest expenditure measured 
by the relative risk of insurance company A in 2010 and 2011 were ACG 5020 and ACG 
4940 respectively. The high relative risk groups were most concentrated in the ACG 
categories starting with the number 17, 4 and 5, which were corresponding to the 
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conditions of pregnancy, patients of high morbidities, and infants respectively. The 
variations of the values of the relative risk increased for most of the ACGs starting with 
the number 5 from 2010 to 2011.   
Table 3.14 ACGs Relative Risk Distributions of Insurance Company A by Years 
ACG 
Number 
ACG Description 2010 
Relative 
Risk 
 
2010 
Population
  % 
 
2010 
Cost  
% 
2011 
Relative 
Risk 
2011 
Population 
 % 
2011 
Cost   
% 
0100 Acute Minor, Age 1 0.368 1.078 0.397 0.433 1.310 0.568 
0200 Acute Minor, Age 2 to 5 0.367 4.026 1.479 0.491 4.492 2.208 
0300 Acute Minor, Age > 5 0.355 26.395 9.376 0.368 24.977 9.203 
0400 Acute Major 0.668 11.392 7.610 0.817 6.338 5.182 
0500 
Likely to Recur, w/o 
Allergies 
0.431 7.909 3.406 0.501 7.036 3.526 
0600 
Likely to Recur, with 
Allergies 
0.263 0.717 0.189 0.380 0.670 0.255 
0700 Asthma 0.491 0.277 0.136 0.522 0.219 0.114 
0800 Chronic Medical, Unstable 2.800 1.333 3.734 2.769 0.787 2.181 
0900 Chronic Medical, Stable 0.837 4.524 3.787 0.919 3.091 2.841 
1000 Chronic Specialty, Stable 0.341 0.353 0.120 0.683 0.166 0.113 
1100 Eye/Dental 0.367 4.030 1.479 0.347 3.464 1.203 
1200 Chronic Specialty, Unstable 0.875 0.083 0.072 0.899 0.081 0.073 
1300 
Psychosocial, w/o Psych 
Unstable 
0.529 0.238 0.126 0.438 0.189 0.083 
1400 
Psychosocial, with Psych 
Unstable, w/o Psych Stable 
1.132 0.030 0.033 1.276 0.034 0.043 
1500 
Psychosocial, with Psych 
Unstable, w/ Psych Stable 
n/a n/a n/a 1.623 0.001 0.002 
1600 Preventive/Administrative 0.439 6.219 2.729 0.453 3.335 1.512 
1711 
Pregnancy: 0-1 ADGs, 
delivered 
3.439 0.744 2.558 2.828 0.503 1.422 
1712 
Pregnancy: 0-1 ADGs, not 
delivered 
1.184 0.570 0.675 1.050 0.434 0.455 
1721 
Pregnancy: 2-3 ADGs, no 
Major ADGs, delivered 
3.963 0.307 1.215 3.632 0.392 1.422 
1722 
Pregnancy: 2-3 ADGs, no 
Major ADGs, not delivered 
1.914 0.264 0.506 1.513 0.534 0.808 
1731 
Pregnancy: 2-3 ADGs, 1+ 
Major ADGs, delivered 
4.996 0.021 0.104 5.497 0.023 0.127 
1732 
Pregnancy: 2-3 ADGs, 1+ 
Major ADGs, not delivered 
2.363 0.053 0.124 2.826 0.080 0.227 
1741 
Pregnancy: 4-5 ADGs, no 
Major ADGs, delivered 
5.024 0.062 0.311 4.368 0.093 0.407 
1742 
Pregnancy: 4-5 ADGs, no 
Major ADGs, not delivered 
3.452 0.081 0.278 2.110 0.186 0.393 
1751 
Pregnancy: 4-5 ADGs, 1+ 
Major ADGs, delivered 
5.759 0.017 0.100 6.841 0.035 0.242 
1752 
Pregnancy: 4-5 ADGs, 1+ 
Major ADGs, not delivered 
4.624 0.032 0.150 3.776 0.068 0.258 
1761 
Pregnancy: 6+ ADGs, no 
Major ADGs, delivered 
6.929 0.029 0.200 5.842 0.032 0.190 
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1762 
Pregnancy: 6+ ADGs, no 
Major ADGs, not delivered 
4.067 0.029 0.117 3.538 0.048 0.168 
1771 
Pregnancy: 6+ ADGs, 1+ 
Major ADGs, delivered 
9.432 0.028 0.265 10.026 0.031 0.307 
1772 
Pregnancy: 6+ ADGs, 1+ 
Major ADGs, not delivered 
7.371 0.038 0.281 6.642 0.063 0.419 
1800 
Acute Minor and Acute 
Major 
1.355 4.487 6.079 1.020 5.492 5.602 
1900 
Acute Minor and Likely to 
Recur, Age 1 
0.935 0.078 0.073 0.886 0.200 0.177 
2000 
Acute Minor and Likely to 
Recur, Age 2 to 5 
1.080 0.310 0.334 0.972 0.711 0.690 
2100 
Acute Minor and Likely to 
Recur, Age > 5, w/o Allergy 
1.002 2.619 2.625 0.802 5.823 4.671 
2200 
Acute Minor and Likely to 
Recur, Age > 5, with 
Allergy 
0.873 0.226 0.197 0.707 0.728 0.515 
2300 
Acute Minor and Chronic 
Medical: Stable 
1.661 1.890 3.140 1.218 2.580 3.143 
2400 
Acute Minor and 
Eye/Dental 
0.970 1.342 1.301 0.680 2.552 1.735 
2500 
Acute Minor and 
Psychosocial, w/o Psych 
Unstable 
1.238 0.096 0.119 0.810 0.174 0.141 
2600 
Acute Minor and 
Psychosocial, with Psych 
Unstable, w/o Psych Stable 
1.205 0.015 0.018 1.179 0.027 0.032 
2700 
Acute Minor and 
Psychosocial, with Psych 
Unstable and Psych Stable 
n/a n/a n/a 0.844 0.001 0.001 
2800 
Acute Minor and Likely to 
Recur 
1.351 1.138 1.538 1.200 1.498 1.798 
2900 
Acute Minor/Acute 
Major/Likely to Recur, Age 
1 
2.294 0.037 0.084 1.417 0.047 0.067 
3000 
Acute Minor/Acute 
Major/Likely to Recur, Age 
2 to 5 
2.372 0.148 0.352 1.779 0.177 0.315 
3100 
Acute Minor/Acute 
Major/Likely to Recur, Age 
6 to 11 
2.521 0.066 0.167 1.414 0.083 0.117 
3200 
Acute Minor/Acute 
Major/Likely to Recur, 
Age > 11, w/o Allergy 
2.059 1.317 2.711 1.470 2.266 3.331 
3300 
Acute Minor/Acute 
Major/Likely to Recur, 
Age > 11, with Allergy 
1.972 0.124 0.244 1.408 0.223 0.313 
3400 
Acute Minor/Likely to 
Recur/Eye & Dental 
1.611 0.389 0.626 1.193 1.049 1.252 
3500 
Acute Minor/Likely to 
Recur/Psychosocial 
1.929 0.033 0.064 1.420 0.095 0.134 
3600 
Acute Minor/Acute 
Major/Likely Recur/Eye & 
Dental 
4.319 0.700 3.022 3.478 0.857 2.979 
3700 
Acute Minor/Acute 
Major/Likely 
Recur/Psychosocial 
4.024 0.039 0.156 2.185 0.055 0.119 
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3800 
2-3 Other ADG 
Combinations, Age < 18 
2.236 0.871 1.948 1.858 0.988 1.835 
3900 
2-3 Other ADG 
Combinations, Males Age 
18 to 34 
1.857 1.067 1.981 1.712 1.557 2.665 
4000 
2-3 Other ADG 
Combinations, Females Age 
18 to 34 
2.260 1.638 3.702 1.689 2.516 4.249 
4100 
2-3 Other ADG 
Combinations, Age > 34 
2.168 2.681 5.812 2.022 2.738 5.536 
4210 
4-5 Other ADG 
Combinations, Age < 18, no 
Major ADGs 
2.872 0.301 0.864 2.255 0.403 0.908 
4220 
4-5 Other ADG 
Combinations, Age < 18, 1+ 
Major ADGs 
3.921 0.168 0.661 4.294 0.163 0.699 
4310 
4-5 Other ADG 
Combinations, Age 18 to 
44, no Major ADGs 
2.818 1.168 3.291 2.038 1.886 3.844 
4320 
4-5 Other ADG 
Combinations, Age 18 to 
44, 1+ Major ADGs 
4.847 0.667 3.235 3.386 1.133 3.836 
4330 
4-5 Other ADG 
Combinations, Age 18 to 
44, 2+ Major ADGs 
5.078 0.094 0.475 6.354 0.203 1.292 
4410 
4-5 Other ADG 
Combinations, Age > 44, no 
Major ADGs 
2.615 0.433 1.134 2.243 0.281 0.631 
4420 
4-5 Other ADG 
Combinations, Age > 44, 1+ 
Major ADGs 
4.724 0.266 1.258 3.748 0.177 0.663 
4430 
4-5 Other ADG 
Combinations, Age > 44, 2+ 
Major ADGs 
6.000 0.035 0.207 9.132 0.038 0.344 
4510 
6-9 Other ADG 
Combinations, Age < 6, no 
Major ADGs 
4.854 0.064 0.311 4.386 0.067 0.295 
4520 
6-9 Other ADG 
Combinations, Age < 6, 1+ 
Major ADGs 
7.636 0.083 0.632 6.852 0.058 0.397 
4610 
6-9 Other ADG 
Combinations, Age 6 to 17, 
no Major ADGs 
3.373 0.014 0.049 4.839 0.021 0.100 
4620 
6-9 Other ADG 
Combinations, Age 6 to 17, 
1+ Major ADGs 
8.082 0.014 0.116 6.916 0.017 0.120 
4710 
6-9 Other ADG 
Combinations, Males, Age 
18 to 34, no Major ADGs 
4.341 0.090 0.391 3.908 0.116 0.454 
4720 
6-9 Other ADG 
Combinations, Males, Age 
18 to 34, 1+ Major ADGs 
6.314 0.091 0.577 5.899 0.106 0.625 
4730 
6-9 Other ADG 
Combinations, Males, Age 
18 to 34, 2+ Major ADGs 
10.746 0.036 0.387 7.655 0.035 0.270 
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4810 
6-9 Other ADG 
Combinations, Females, 
Age 18 to 34, no Major 
ADGs 
4.609 0.167 0.770 3.194 0.239 0.762 
4820 
6-9 Other ADG 
Combinations, Females, 
Age 18 to 34, 1+ Major 
ADGs 
6.479 0.196 1.269 5.105 0.220 1.124 
4830 
6-9 Other ADG 
Combinations, Females, 
Age 18 to 34, 2+ Major 
ADGs 
7.886 0.051 0.403 7.759 0.090 0.701 
4910 
6-9 Other ADG 
Combinations, Age > 34, 0-
1 Major ADGs 
6.158 0.331 2.039 4.512 0.380 1.716 
4920 
6-9 Other ADG 
Combinations, Age > 34, 2 
Major ADGs 
8.824 0.056 0.496 9.149 0.074 0.676 
4930 
6-9 Other ADG 
Combinations, Age > 34, 3 
Major ADGs 
12.872 0.006 0.074 7.033 0.014 0.099 
4940 
6-9 Other ADG 
Combinations, Age > 34, 4+ 
Major ADGs 
n/a n/a n/a 23.270 0.001 0.022 
5010 
10+ Other ADG 
Combinations, Age 1 to 17, 
no Major ADGs 
5.688 0.002 0.012 15.941 0.002 0.038 
5020 
10+ Other ADG 
Combinations, Age 1 to 17, 
1 Major ADGs 
15.836 0.005 0.080 16.773 0.005 0.087 
5030 
10+ Other ADG 
Combinations, Age 1 to 17, 
2 Major ADGs 
7.122 0.003 0.021 10.228 0.001 0.014 
5040 
10+ Other ADG 
Combinations, Age > 17, 0-
1 Major ADGs 
9.785 0.022 0.218 9.388 0.030 0.278 
5050 
10+ Other ADG 
Combinations, Age > 17, 2 
Major ADGs 
12.196 0.020 0.246 7.363 0.016 0.118 
5060 
10+ Other ADG 
Combinations, Age > 17, 3 
Major ADGs 
12.403 0.006 0.080 15.011 0.008 0.120 
5070 
10+ Other ADG 
Combinations, Age > 17, 4+ 
Major ADGs 
n/a n/a n/a 8.572 0.001 0.012 
5110 
No Diagnosis or Only 
Unclassified Diagnosis (2 
input files) 
0.622 1.666 1.036 0.628 1.670 1.050 
5311 
Infants: 0-5 ADGs, no 
Major ADGs, low birth 
weight 
n/a n/a n/a 1.929 0.000 0.001 
5312 
Infants: 0-5 ADGs, no 
Major ADGs, normal birth 
weight 
0.768 1.625 1.247 0.765 1.302 0.996 
5322 
Infants: 0-5 ADGs, 1+ 
Major ADGs, normal birth 
weight 
3.513 0.102 0.357 3.409 0.082 0.281 
 79 
 
 
Figure 3.11 Compare Two Years’ ACGs Relative Risk Distributions for Insurance 
Company A 
  
 Table 3.15 summarized the distributions of the relative risk among all the 
observed ACG categories of insurance company B in 2010 and 2011. In addition, the 
associated percentages of each ACG category in the populations as well as the associated 
cost percentages of each ACG in the total cost of insurance company B were listed in 
Table 3.15 according to years. Compared with the two years’ distributions of the relative 
risk in Figure 3.12, most of the ACGs which existed in both two years showed some 
similarities in 2010 and 2011. The ACG categories of the highest expenditure measured 
by the relative risk of insurance company B in 2010 and 2011 were ACG 4220 and ACG 
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4430 respectively. In 2011, ACG 800, ACG 1000 and ACG 4430 showed a significant 
increase in degree of relative risk in comparison with those ACGs in 2010. On the 
contrary, compared with the year 2010, the relative risk of the ACG 700, ACG 3000 and 
ACG 4210 showed a significant decrease in 2011. ACG 4920 and ACG 4930, which 
showed considerably high relative risk in 2010, were not observed in the population of 
insurance company B in 2011. Of those ACGs with a high relative risk, ACG 4420 and 
ACG 4720 were only observed in 2011. In 2010, several ACG categories of extremely 
high expenditures were ACG 3000, ACG 4210, ACG 4910, ACG 4920, and ACG 4930 
corresponding to recurred acute minor or major conditions for young people and 
populations with a high morbidity burden, whereas those categories in 2011 were ACGs 
800, ACG 1000, ACG 4420, ACG 4430 and ACG 4830 corresponding to populations 
with chronic conditions as well as high morbidity burdens.  
Table 3.15 ACGs Relative Risk Distributions of Insurance Company B by Years 
ACG 
Number 
ACG Description 
2010 
Relative 
Risk 
2010 
Population   
% 
2010      
Cost  
% 
2011 
 Relative 
 Risk 
2011 
Population  
 % 
2011 
Cost  
% 
100 Acute Minor, Age 1 0.072 0.033 0.002 0.672 1.673 1.125 
200 Acute Minor, Age 2 to 5 0.68 5.816 3.954 0.762 8.421 6.42 
300 Acute Minor, Age > 5 0.474 36.823 17.469 0.453 34.126 15.445 
400 Acute Major 1.335 9.239 12.332 1.302 9.126 11.879 
500 Likely to Recur, w/o Allergies 0.884 8.475 7.492 0.715 7.629 5.457 
600 
Likely to Recur, with 
Allergies 
0.571 0.665 0.38 0.501 0.469 0.235 
700 Asthma 1.859 0.233 0.432 0.893 0.411 0.367 
800 Chronic Medical, Unstable 2.863 0.964 2.759 7.85 0.822 6.449 
900 Chronic Medical, Stable 1.135 2.725 3.092 1.249 2.113 2.638 
1000 Chronic Specialty, Stable 0.204 0.233 0.048 3.469 0.293 1.018 
1100 Eye/Dental 0.404 2.725 1.1 0.485 3.052 1.48 
1200 Chronic Specialty, Unstable 0.062 0.066 0.004 0.573 0.117 0.067 
1300 
Psychosocial, w/o Psych 
Unstable 
0.063 0.033 0.002 1.956 0.029 0.057 
1600 Preventive/Administrative 0.604 0.166 0.1 0.388 0.352 0.137 
1711 
Pregnancy: 0-1 ADGs, 
delivered 
 n/a   n/a   n/a  0.239 0.059 0.014 
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1712 
Pregnancy: 0-1 ADGs, not 
delivered 
0.202 0.133 0.027 0.136 0.088 0.012 
1721 
Pregnancy: 2-3 ADGs, no 
Major ADGs, delivered 
0.59 0.066 0.039 2.651 0.029 0.078 
1722 
Pregnancy: 2-3 ADGs, no 
Major ADGs, not delivered 
0.818 0.133 0.109 1.327 0.117 0.156 
1742 
Pregnancy: 4-5 ADGs, no 
Major ADGs, not delivered 
 n/a   n/a   n/a  1.388 0.059 0.081 
1752 
Pregnancy: 4-5 ADGs, 1+ 
Major ADGs, not delivered 
0.875 0.033 0.029  n/a   n/a   n/a  
1800 Acute Minor and Acute Major 1.061 7.81 8.284 1.093 6.191 6.767 
1900 
Acute Minor and Likely to 
Recur, Age 1 
 n/a n/a  n/a  0.34 0.059 0.02 
2000 
Acute Minor and Likely to 
Recur, Age 2 to 5 
0.751 0.631 0.474 1.523 0.792 1.206 
2100 
Acute Minor and Likely to 
Recur, Age > 5, w/o Allergy 
1.001 5.616 5.621 1.005 6.25 6.279 
2200 
Acute Minor and Likely to 
Recur, Age > 5, with Allergy 
0.687 0.432 0.297 0.743 0.323 0.24 
2300 
Acute Minor and Chronic 
Medical: Stable 
1.043 1.263 1.317 1.241 1.496 1.857 
2400 Acute Minor and Eye/Dental 0.933 2.027 1.891 0.802 2.523 2.024 
2500 
Acute Minor and 
Psychosocial, w/o Psych 
Unstable 
 n/a   n/a   n/a  1.913 0.059 0.112 
2800 
Acute Minor and Likely to 
Recur 
1.43 1.994 2.851 1.701 1.555 2.645 
3000 
Acute Minor/Acute 
Major/Likely to Recur, Age 2 
to 5 
0.774 0.133 0.103 0.52 0.059 0.031 
3100 
Acute Minor/Acute 
Major/Likely to Recur, Age 6 
to 11 
4.594 0.033 0.153 0.407 0.029 0.012 
3200 
Acute Minor/Acute 
Major/Likely to Recur, Age > 
11, w/o Allergy 
1.828 2.227 4.07 1.776 1.995 3.544 
3300 
Acute Minor/Acute 
Major/Likely to Recur, Age > 
11, with Allergy 
1.402 0.133 0.186 2.146 0.147 0.315 
3400 
Acute Minor/Likely to 
Recur/Eye & Dental 
1.346 0.532 0.716 1.322 0.558 0.737 
3600 
Acute Minor/Acute 
Major/Likely Recur/Eye & 
Dental 
2.313 0.266 0.615 3.276 0.411 1.346 
3800 
2-3 Other ADG 
Combinations, Age < 18 
3.121 0.465 1.452 1.101 0.411 0.452 
3900 
2-3 Other ADG 
Combinations, Males Age 18 
to 34 
1.845 1.23 2.269 1.386 0.734 1.017 
4000 
2-3 Other ADG 
Combinations, Females Age 
18 to 34 
2.21 1.695 3.745 1.596 1.966 3.139 
4100 
2-3 Other ADG 
Combinations, Age > 34 
3.792 2.625 9.956 2.566 2.582 6.626 
4210 
4-5 Other ADG 
Combinations, Age < 18, no 
Major ADGs 
0.809 0.033 0.027 2.185 0.088 0.192 
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4220 
4-5 Other ADG 
Combinations, Age < 18, 1+ 
Major ADGs 
8.017 0.033 0.266 2.806 0.029 0.082 
4310 
4-5 Other ADG 
Combinations, Age 18 to 44, 
no Major ADGs 
1.522 0.499 0.759 1.949 1.115 2.174 
4320 
4-5 Other ADG 
Combinations, Age 18 to 44, 
1+ Major ADGs 
2.805 0.299 0.839 2.36 0.558 1.316 
4330 
4-5 Other ADG 
Combinations, Age 18 to 44, 
2+ Major ADGs 
1.388 0.066 0.092 4.177 0.088 0.368 
4410 
4-5 Other ADG 
Combinations, Age > 44, no 
Major ADGs 
2.503 0.233 0.582 1.957 0.059 0.115 
4420 
4-5 Other ADG 
Combinations, Age > 44, 1+ 
Major ADGs 
2.563 0.133 0.341 7.274 0.147 1.067 
4430 
4-5 Other ADG 
Combinations, Age > 44, 2+ 
Major ADGs 
 n/a   n/a   n/a  25.059 0.059 1.471 
4520 
6-9 Other ADG 
Combinations, Age < 6, 1+ 
Major ADGs 
0.784 0.033 0.026  n/a   n/a   n/a  
4710 
6-9 Other ADG 
Combinations, Males, Age 18 
to 34, no Major ADGs 
1.388 0.1 0.138 2.671 0.029 0.078 
4720 
6-9 Other ADG 
Combinations, Males, Age 18 
to 34, 1+ Major ADGs 
0.743 0.033 0.025 6.199 0.029 0.182 
4730 
6-9 Other ADG 
Combinations, Males, Age 18 
to 34, 2+ Major ADGs 
 n/a   n/a   n/a  1.314 0.029 0.039 
4810 
6-9 Other ADG 
Combinations, Females, Age 
18 to 34, no Major ADGs 
 n/a   n/a   n/a  1.901 0.088 0.167 
4820 
6-9 Other ADG 
Combinations, Females, Age 
18 to 34, 1+ Major ADGs 
2.276 0.133 0.303 2.682 0.059 0.157 
4830 
6-9 Other ADG 
Combinations, Females, Age 
18 to 34, 2+ Major ADGs 
2.224 0.1 0.222 4.208 0.088 0.37 
4910 
6-9 Other ADG 
Combinations, Age > 34, 0-1 
Major ADGs 
2.257 0.066 0.15 2.934 0.176 0.517 
4920 
6-9 Other ADG 
Combinations, Age > 34, 2 
Major ADGs 
4.914 0.133 0.653  n/a   n/a   n/a  
4930 
6-9 Other ADG 
Combinations, Age > 34, 3 
Major ADGs 
7.009 0.033 0.233  n/a   n/a   n/a  
5110 
No Diagnosis or Only 
Unclassified Diagnosis (2 
input files) 
4.947 0.399 1.973 0.941 0.235 0.221 
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Figure 3.12 Compare Two Years’ ACGs Relative Risk Distributions for Insurance 
Company B 
 
 Table 3.16 summarized the distributions of relative risk among all the observed 
ACG categories of insurance company C in 2010 and 2011. In addition, the associated 
percentages of each ACG category in the populations as well as the associated cost 
percentages of each ACG in the total cost of insurance company C were listed according 
to years. Comparing the two years’ distributions in Table 3.16, most of the ACGs which 
existed in both two years showed different distributions patterns of relative risk in 2010 
and 2011. The ACG categories of the highest expenditure of insurance company C in 
2010 and 2011 were ACG 4910 and ACG 5060 respectively. Few high relative risk 
groups were observed in the population from insurance company C in 2010. The two 
highest relative risk groups for the population of insurance company C in 2010 were 
ACG 800 and ACG 4910 with the values of about 2. In addition, compared with other 
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insurance companies, the values of the relative risk of the ACG categories of insurance 
company C in 2010 showed a very different pattern of distribution. With less variance, 
the values of the relative risk of ACGs of insurance company C in 2010 converged at 1. 
By contrast, compared with the year 2010, the distribution of the values of the relative 
risk of ACG categories of insurance company C showed more varieties in 2011. The 
highest expenditure ACG category was ACG 5060, ACG 800, ACG 1400, and some of 
the ACGs starting with numbers 17, 4 and 5, which were corresponding to the conditions 
of unstable chronic patients, patients of unstable psychological, pregnancy, patients of 
high morbidities, and infants respectively.  
Table 3.16 ACGs Relative Risk Distributions of Insurance Company C by Years 
ACG 
Number 
ACG Description 
2010 
Relative 
Risk 
2010 
Population 
 % 
2010 
Cost 
% 
2011  
Relative 
Risk 
2011 
Population
 % 
2011 
Cost 
% 
0100 Acute Minor, Age 1 0.041 0.100 0.004 0.204 1.003 0.205 
0200 Acute Minor, Age 2 to 5 0.041 0.564 0.023 0.238 3.108 0.740 
0300 Acute Minor, Age > 5 1.096 15.008 16.455 0.891 20.876 18.608 
0400 Acute Major 0.785 11.417 8.965 1.744 11.357 19.811 
0500 Likely to Recur, w/o Allergies 0.409 4.998 2.043 0.700 4.241 2.968 
0600 Likely to Recur, with Allergies 0.103 0.085 0.009 0.170 0.390 0.067 
0700 Asthma 0.426 0.162 0.069 0.411 0.082 0.034 
0800 Chronic Medical, Unstable 1.910 15.379 29.378 6.642 0.969 6.435 
0900 Chronic Medical, Stable 1.062 10.258 10.896 1.540 1.730 2.664 
1000 Chronic Specialty, Stable 1.432 0.888 1.272 0.917 0.259 0.238 
1100 Eye/Dental 0.158 1.475 0.233 0.223 2.093 0.467 
1200 Chronic Specialty, Unstable 0.892 0.124 0.110 2.160 0.057 0.124 
1300 
Psychosocial, w/o Psych 
Unstable 
0.129 0.062 0.008 0.281 0.258 0.072 
1400 
Psychosocial, with Psych 
Unstable, w/o Psych Stable 
1.259 0.070 0.088 4.530 0.009 0.042 
1500 
Psychosocial, with Psych 
Unstable, w/ Psych Stable 
0.251 0.008 0.002 2.011 0.001 0.001 
1600 Preventive/Administrative 0.758 2.441 1.849 0.484 8.697 4.206 
1711 
Pregnancy: 0-1 ADGs, 
delivered 
0.592 0.216 0.128 2.114 0.407 0.860 
1712 
Pregnancy: 0-1 ADGs, not 
delivered 
0.160 0.093 0.015 0.632 0.279 0.176 
1721 
Pregnancy: 2-3 ADGs, no 
Major ADGs, delivered 
n/a n/a n/a 2.549 0.202 0.515 
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1722 
Pregnancy: 2-3 ADGs, no 
Major ADGs, not delivered 
0.093 0.100 0.009 0.674 0.360 0.243 
1731 
Pregnancy: 2-3 ADGs, 1+ 
Major ADGs, delivered 
n/a n/a n/a 3.061 0.029 0.090 
1732 
Pregnancy: 2-3 ADGs, 1+ 
Major ADGs, not delivered 
0.271 0.008 0.002 1.227 0.055 0.068 
1741 
Pregnancy: 4-5 ADGs, no 
Major ADGs, delivered 
n/a n/a n/a 3.048 0.054 0.166 
1742 
Pregnancy: 4-5 ADGs, no 
Major ADGs, not delivered 
0.127 0.015 0.002 1.068 0.160 0.171 
1751 
Pregnancy: 4-5 ADGs, 1+ 
Major ADGs, delivered 
n/a n/a n/a 3.103 0.013 0.040 
1752 
Pregnancy: 4-5 ADGs, 1+ 
Major ADGs, not delivered 
0.216 0.008 0.001 1.241 0.051 0.063 
1761 
Pregnancy: 6+ ADGs, no 
Major ADGs, delivered 
n/a n/a n/a 2.466 0.017 0.042 
1762 
Pregnancy: 6+ ADGs, no 
Major ADGs, not delivered 
0.079 0.008 0.002 1.387 0.058 0.080 
1771 
Pregnancy: 6+ ADGs, 1+ 
Major ADGs, delivered 
n/a n/a n/a 3.785 0.013 0.049 
1772 
Pregnancy: 6+ ADGs, 1+ 
Major ADGs, not delivered 
0.156 0.015 0.923 1.937 0.039 0.075 
1800 Acute Minor and Acute Major 0.360 2.564 0.004 0.582 6.384 3.712 
1900 
Acute Minor and Likely to 
Recur, Age 1 
0.163 0.023 0.003 0.347 0.194 0.067 
2000 
Acute Minor and Likely to 
Recur, Age 2 to 5 
0.055 0.062 0.230 0.436 0.644 0.281 
2100 
Acute Minor and Likely to 
Recur, Age > 5, w/o Allergy 
0.146 1.576 0.008 0.336 4.317 1.451 
2200 
Acute Minor and Likely to 
Recur, Age > 5, with Allergy 
0.085 0.093 0.389 0.285 0.564 0.161 
2300 
Acute Minor and Chronic 
Medical: Stable 
0.362 1.074 0.029 0.500 1.335 0.668 
2400 Acute Minor and Eye/Dental 0.057 0.502 0.008 0.296 2.211 0.655 
2500 
Acute Minor and Psychosocial, 
w/o Psych Unstable 
0.109 0.077 0.007 0.346 0.215 0.074 
2600 
Acute Minor and Psychosocial, 
with Psych Unstable, w/o 
Psych Stable 
0.903 0.008 0.435 0.243 0.008 0.002 
2700 
Acute Minor and Psychosocial, 
with Psych Unstable and Psych 
Stable 
n/a n/a n/a 0.519 0.001 0.000 
2800 
Acute Minor and Likely to 
Recur 
0.411 1.058 0.001 0.644 1.484 0.955 
2900 
Acute Minor/Acute 
Major/Likely to Recur, Age 1 
n/a n/a n/a 0.576 0.094 0.054 
3000 
Acute Minor/Acute 
Major/Likely to Recur, Age 2 
to 5 
n/a n/a n/a 0.677 0.352 0.239 
3100 
Acute Minor/Acute 
Major/Likely to Recur, Age 6 
to 11 
0.108 0.008 0.365 0.499 0.133 0.066 
3200 
Acute Minor/Acute 
Major/Likely to Recur, Age > 
11, w/o Allergy 
0.261 1.398 0.032 0.712 2.894 2.061 
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3300 
Acute Minor/Acute 
Major/Likely to Recur, Age > 
11, with Allergy 
0.246 0.131 0.018 0.564 0.305 0.172 
3400 
Acute Minor/Likely to 
Recur/Eye & Dental 
0.132 0.139 0.001 0.447 0.921 0.412 
3500 
Acute Minor/Likely to 
Recur/Psychosocial 
0.048 0.031 0.432 0.588 0.117 0.069 
3600 
Acute Minor/Acute 
Major/Likely Recur/Eye & 
Dental 
0.331 1.305 0.034 1.234 1.052 1.298 
3700 
Acute Minor/Acute 
Major/Likely 
Recur/Psychosocial 
0.364 0.093 0.010 0.887 0.134 0.119 
3800 
2-3 Other ADG Combinations, 
Age < 18 
0.143 0.070 0.167 0.507 0.605 0.307 
3900 
2-3 Other ADG Combinations, 
Males Age 18 to 34 
0.297 0.564 0.257 0.690 1.259 0.869 
4000 
2-3 Other ADG Combinations, 
Females Age 18 to 34 
0.346 0.742 8.197 0.624 1.732 1.080 
4100 
2-3 Other ADG Combinations, 
Age > 34 
0.922 8.891 0.004 2.268 3.379 7.664 
4210 
4-5 Other ADG Combinations, 
Age < 18, no Major ADGs 
0.132 0.031 0.001 0.739 0.481 0.356 
4220 
4-5 Other ADG Combinations, 
Age < 18, 1+ Major ADGs 
0.057 0.015 0.136 1.022 0.125 0.127 
4310 
4-5 Other ADG Combinations, 
Age 18 to 44, no Major ADGs 
0.180 0.757 0.219 0.693 2.239 1.550 
4320 
4-5 Other ADG Combinations, 
Age 18 to 44, 1+ Major ADGs 
0.243 0.904 0.026 1.415 1.000 1.415 
4330 
4-5 Other ADG Combinations, 
Age 18 to 44, 2+ Major ADGs 
0.258 0.100 0.358 3.250 0.137 0.444 
4410 
4-5 Other ADG Combinations, 
Age > 44, no Major ADGs 
0.291 1.228 2.403 1.050 0.779 0.818 
4420 
4-5 Other ADG Combinations, 
Age > 44, 1+ Major ADGs 
0.571 4.210 0.674 2.716 0.817 2.219 
4430 
4-5 Other ADG Combinations, 
Age > 44, 2+ Major ADGs 
0.656 1.027 0.003 7.137 0.163 1.165 
4510 
6-9 Other ADG Combinations, 
Age < 6, no Major ADGs 
n/a n/a n/a 1.407 0.084 0.119 
4520 
6-9 Other ADG Combinations, 
Age < 6, 1+ Major ADGs 
0.337 0.008 0.014 1.413 0.038 0.054 
4610 
6-9 Other ADG Combinations, 
Age 6 to 17, no Major ADGs 
n/a n/a n/a 0.857 0.055 0.047 
4620 
6-9 Other ADG Combinations, 
Age 6 to 17, 1+ Major ADGs 
n/a n/a n/a 1.743 0.019 0.034 
4710 
6-9 Other ADG Combinations, 
Males, Age 18 to 34, no Major 
ADGs 
0.919 0.015 0.027 1.075 0.143 0.154 
4720 
6-9 Other ADG Combinations, 
Males, Age 18 to 34, 1+ Major 
ADGs 
0.353 0.077 0.010 1.243 0.095 0.117 
4730 
6-9 Other ADG Combinations, 
Males, Age 18 to 34, 2+ Major 
ADGs 
0.220 0.046 0.012 3.705 0.029 0.106 
4810 
6-9 Other ADG Combinations, 
Females, Age 18 to 34, no 
Major ADGs 
0.194 0.062 0.019 0.978 0.358 0.350 
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4820 
6-9 Other ADG Combinations, 
Females, Age 18 to 34, 1+ 
Major ADGs 
0.345 0.054 0.016 1.476 0.253 0.373 
4830 
6-9 Other ADG Combinations, 
Females, Age 18 to 34, 2+ 
Major ADGs 
0.412 0.039 10.524 2.087 0.053 0.111 
4910 
6-9 Other ADG Combinations, 
Age > 34, 0-1 Major ADGs 
2.455 4.287 1.476 1.903 1.754 3.338 
4920 
6-9 Other ADG Combinations, 
Age > 34, 2 Major ADGs 
0.746 1.977 0.316 3.515 0.423 1.488 
4930 
6-9 Other ADG Combinations, 
Age > 34, 3 Major ADGs 
0.952 0.332 0.005 6.127 0.055 0.338 
4940 
6-9 Other ADG Combinations, 
Age > 34, 4+ Major ADGs 
0.300 0.015 0.017 7.815 0.003 0.022 
5010 
10+ Other ADG Combinations, 
Age 1 to 17, no Major ADGs 
n/a n/a n/a 0.693 0.001 0.000 
5020 
10+ Other ADG Combinations, 
Age 1 to 17, 1 Major ADGs 
n/a n/a n/a 2.316 0.001 0.003 
5040 
10+ Other ADG Combinations, 
Age > 17, 0-1 Major ADGs 
0.283 0.062 0.059 3.778 0.116 0.438 
5050 
10+ Other ADG Combinations, 
Age > 17, 2 Major ADGs 
0.362 0.162 0.046 4.090 0.084 0.346 
5060 
10+ Other ADG Combinations, 
Age > 17, 3 Major ADGs 
0.747 0.062 0.512 11.896 0.028 0.332 
5070 
10+ Other ADG Combinations, 
Age > 17, 4+ Major ADGs 
n/a n/a n/a 8.537 0.007 0.061 
5110 
No Diagnosis or Only 
Unclassified Diagnosis (2 input 
files) 
1.380 0.371 0.007 1.375 1.073 1.475 
5312 
Infants: 0-5 ADGs, no Major 
ADGs, normal birth weight 
0.030 0.247 0.000 1.549 0.001 0.002 
5312 
Infants: 0-5 ADGs, no Major 
ADGs, normal birth weight 
n/a n/a n/a 0.320 2.269 0.726 
5322 
Infants: 0-5 ADGs, 1+ Major 
ADGs, normal birth weight 
n/a n/a n/a 1.074 0.073 0.078 
5332 
Infants: 6+ ADGs, no Major 
ADGs, normal birth weight 
n/a n/a n/a 0.881 0.032 0.028 
5342 
Infants: 6+ ADGs, 1+ Major 
ADGs, normal birth weight 
n/a n/a n/a 0.791 0.011 0.009 
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Figure 3.13 Compare Two Years’ ACGs Relative Risk Distributions for Insurance 
Company C 
 
 Table 3.17 summarized the distributions of relative risk among all the observed 
ACG categories of the hospital A in 2010 and 2011. In addition, the associated 
percentages of each ACG category in the populations as well as the associated cost 
percentages of each ACG in the total cost of hospital A were listed in Table 3.17 
according to years. Comparing with the distributions of relative risk in 2010 and 2011 in 
Figure 3.14, most of the ACGs which existed in both years showed similar distributions 
in those two years. The ACG category of the highest expenditure of hospital A in 2010 
was ACG 4420. In addition, in 2011, ACG 1731 and ACG 4430 showed a significant 
increase of relative risk in comparison with those ACGs in 2010. In 2010, several ACGs 
categories of the extremely high expenditures were ACG 1800, ACG 4220, ACG 4100, 
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and ACG 4430. These corresponded to acute minor or major conditions, young and 
middle-age patients with high morbidity burden, whereas those categories in 2011 were 
ACG 1731, ACG 1800, ACG 4100, and ACG 4430 which corresponded to pregnancy 
with major conditions, acute minor or major conditions, adults with high morbidity 
burden. 
Table 3.17 ACGs Relative Risk Distributions of Hospital A by Years 
ACG 
Number 
ACG Description 2010 
Relative 
Risk 
2010 
Population 
% 
2010 
Cost 
% 
2011 
Relative 
Risk 
2011 
Population 
% 
2011 
Cost 
% 
100 Acute Minor, Age 1 0.264 2.785 0.736 0.278 2.584 0.719 
200 Acute Minor, Age 2 to 5 0.295 4.301 1.267 0.302 4.053 1.225 
300 Acute Minor, Age > 5 0.751 12.575 9.444 0.723 12.071 8.729 
400 Acute Major 1.114 19.316 
21.51
7 
1.155 18.458 21.312 
500 Likely to Recur, w/o Allergies 0.671 8.529 5.722 0.633 7.795 4.936 
600 Likely to Recur, with Allergies  n/a 0 0 0.361 0.007 0.002 
700 Asthma 0.564 0.193 0.109 0.4 0.162 0.065 
800 Chronic Medical, Unstable 1.27 23.753 
30.16
4 
1.274 27.287 34.777 
900 Chronic Medical, Stable 0.87 7.215 6.276 0.883 7.797 6.884 
1000 Chronic Specialty, Stable 0.919 0.725 0.666 0.828 0.955 0.791 
1100 Eye/Dental 0.611 1.123 0.687 0.499 1.104 0.551 
1200 Chronic Specialty, Unstable 1.161 0.615 0.714 1.024 0.5 0.512 
1300 
Psychosocial, w/o Psych 
Unstable 
0.809 0.262 0.212 0.506 0.351 0.178 
1400 
Psychosocial, with Psych 
Unstable, w/o Psych Stable 
0.319 0.031 0.01 1.69 0.027 0.046 
1600 Preventive/Administrative 2.481 3.522 8.738 1.766 3.652 6.449 
1711 Pregnancy: 0-1 ADGs, delivered 0.366 6.7 2.454 0.338 5.927 2.006 
1712 
Pregnancy: 0-1 ADGs, not 
delivered 
0.149 0.131 0.02 0.16 0.171 0.027 
1721 
Pregnancy: 2-3 ADGs, no Major 
ADGs, delivered 
0.767 0.019 0.015 0.9 0.016 0.014 
1731 
Pregnancy: 2-3 ADGs, 1+ Major 
ADGs, delivered 
0.56 0.005 0.003 3.999 0.007 0.027 
1800 Acute Minor and Acute Major 3.455 0.069 0.239 2.737 0.088 0.24 
2000 
Acute Minor and Likely to 
Recur, Age 2 to 5 
0.822 0.002 0.002 0.444 0.005 0.002 
2100 
Acute Minor and Likely to 
Recur, Age > 5, w/o Allergy 
1.331 0.038 0.051 1.66 0.052 0.086 
2300 
Acute Minor and Chronic 
Medical: Stable 
2.073 0.029 0.059 1.823 0.041 0.074 
2400 Acute Minor and Eye/Dental 0.954 0.007 0.007 0.568 0.002 0.001 
2500 
Acute Minor and Psychosocial, 
w/o Psych Unstable 
0.282 0.002 0.001 0.383 0.002 0.001 
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2800 
Acute Minor and Likely to 
Recur 
2.356 0.114 0.27 2.391 0.101 0.242 
3800 
2-3 Other ADG Combinations, 
Age < 18 
0.991 0.033 0.033 1.429 0.027 0.039 
3900 
2-3 Other ADG Combinations, 
Males Age 18 to 34 
2.289 0.01 0.022 2.139 0.011 0.024 
4000 
2-3 Other ADG Combinations, 
Females Age 18 to 34 
1.448 0.024 0.035 2.61 0.014 0.035 
4100 
2-3 Other ADG Combinations, 
Age > 34 
3.076 1.03 3.168 2.93 1.212 3.552 
4420 
4-5 Other ADG Combinations, 
Age > 44, 1+ Major ADGs 
3.602 0.002 0.009  n/a n/a n/a 
4430 
4-5 Other ADG Combinations, 
Age > 44, 2+ Major ADGs 
3.116 0.002 0.007 5.725 0.005 0.026 
5110 
No Diagnosis or Only 
Unclassified Diagnosis (2 input 
files) 
1.278 5.477 7.002 1.383 4.445 6.147 
5312 
Infants: 0-5 ADGs, no Major 
ADGs, normal birth weight 
0.247 1.323 0.327 0.259 1.043 0.27 
5322 
Infants: 0-5 ADGs, 1+ Major 
ADGs, normal birth weight 
0.533 0.036 0.019 0.407 0.027 0.011 
 
Figure 3.14 Compare Two Years’ ACGs Relative Risk Distributions Hospital A 
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 Table 3.18 summarized the distributions of relative risk among all the observed 
ACG categories of hospital B in 2010 and 2011. In addition, the associated percentages 
of each ACG category in the populations as well as the associated cost percentages of 
each ACG in the total cost of hospital B were listed in Table 3.18 according to years.  
Compared with the distributions of relative risk in 2010 and 2011 in Figure 3.15, most of 
the ACGs which existed in both years were similar. The ACG categories of the highest 
expenditure of hospital B in 2010 and 2011 were ACG 4100 and ACG 4000 respectively. 
Additionally, in 2011, the relative values of ACG 1200, and ACG 4000 showed a 
moderate increase in comparison with those ACGs in 2010. By contrast, in 2011, the 
value of the relative risk of ACG 1732 showed a moderate decrease in comparison with 
its value in 2010. In 2010, several ACG categories of extremely high expenditures were 
ACG 1732, ACG 2800, and ACG 4100 which corresponded to pregnancy, likely 
recurring acute minor conditions, and patients with high morbidity burden, whereas those 
categories in 2011 were ACG 4000 and ACG 4100 corresponding to adults with high 
morbidities. 
Table 3.18 ACGs Relative Risk Distributions of Hospital B by Years 
ACG 
Number 
ACG Description 
2010 
Relative 
Risk 
2010 
Population 
% 
2010 
Cost 
% 
2011 
Relative 
Risk 
2011 
Populatio
n % 
2011 
Cost % 
100 Acute Minor, Age 1 0.33 0.226 0.075 0.271 3.163 0.858 
200 Acute Minor, Age 2 to 5 0.223 6.362 1.42 0.272 4.568 1.242 
300 Acute Minor, Age > 5 0.73 11.023 8.046 0.747 10.571 7.899 
400 Acute Major 1.328 26.531 35.23 1.376 24.822 34.152 
500 Likely to Recur, w/o Allergies 0.728 10.202 7.43 0.681 9.476 6.451 
600 Likely to Recur, with Allergies n/a n/a n/a 0.263 0.003 0.001 
700 Asthma 0.794 0.8 0.636 0.849 0.86 0.73 
800 Chronic Medical, Unstable 1.472 17.83 26.25 1.501 17.347 26.033 
900 Chronic Medical, Stable 0.825 8.756 7.222 0.942 9.733 9.165 
1000 Chronic Specialty, Stable 0.858 0.711 0.611 0.678 0.65 0.441 
1100 Eye/Dental 0.543 0.424 0.23 0.59 0.441 0.26 
1200 Chronic Specialty, Unstable 0.725 0.178 0.129 1.686 0.187 0.316 
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1300 
Psychosocial, w/o Psych 
Unstable 
0.66 0.051 0.034 0.458 0.073 0.033 
1400 
Psychosocial, with Psych 
Unstable, w/o Psych Stable 
0.741 0.038 0.028 1.218 0.041 0.05 
1600 Preventive/Administrative 1.452 2.832 4.111 1.275 3.766 4.802 
1711 
Pregnancy: 0-1 ADGs, 
delivered 
0.28 5.883 1.649 0.264 3.284 0.868 
1712 
Pregnancy: 0-1 ADGs, not 
delivered 
0.481 6.567 3.157 0.394 9.565 3.768 
1721 
Pregnancy: 2-3 ADGs, no 
Major ADGs, delivered 
0.902 0.017 0.015 1.54 0.01 0.015 
1722 
Pregnancy: 2-3 ADGs, no 
Major ADGs, not delivered 
0.817 0.048 0.039 0.483 0.044 0.021 
1731 
Pregnancy: 2-3 ADGs, 1+ 
Major ADGs, delivered 
1.243 0.003 0.004 n/a n/a n/a 
1732 
Pregnancy: 2-3 ADGs, 1+ 
Major ADGs, not delivered 
3.191 0.003 0.011 1.058 0.029 0.03 
1800 Acute Minor and Acute Major 1.72 0.123 0.212 0.781 0.136 0.107 
1900 
Acute Minor and Likely to 
Recur, Age 1 
n/a n/a  n/a 0.748 0.003 0.002 
2000 
Acute Minor and Likely to 
Recur, Age 2 to 5 
0.39 0.007 0.003 0.81 0.006 0.005 
2100 
Acute Minor and Likely to 
Recur, Age > 5, w/o Allergy 
1.016 0.041 0.042 1.13 0.01 0.011 
2300 
Acute Minor and Chronic 
Medical: Stable 
2.043 0.048 0.098 1.773 0.051 0.09 
2400 Acute Minor and Eye/Dental n/a n/a n/a 0.781 0.003 0.002 
2800 
Acute Minor and Likely to 
Recur 
3.392 0.096 0.325 2.156 0.067 0.144 
2900 
Acute Minor/Acute 
Major/Likely to Recur, Age 1 
n/a n/a  n/a 0.46 0.003 0.001 
3800 
2-3 Other ADG Combinations, 
Age < 18 
0.532 0.021 0.011 1.294 0.032 0.041 
3900 
2-3 Other ADG Combinations, 
Males Age 18 to 34 
n/a n/a n/a 0.562 0.019 0.011 
4000 
2-3 Other ADG Combinations, 
Females Age 18 to 34 
1.876 0.007 0.013 3.573 0.01 0.034 
4100 
2-3 Other ADG Combinations, 
Age > 34 
3.512 0.691 2.426 2.949 0.66 1.946 
5110 
No Diagnosis or Only 
Unclassified Diagnosis (2 input 
files) 
1.127 0.482 0.543 1.281 0.368 0.471 
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Figure 3.15 Compare Two Years’ ACGs Relative Risk Distributions Hospital B 
 
 Table 3.19 summarized the distributions of relative risk among all the observed 
ACG categories of hospital C in 2010 and 2011. In addition, the associated percentages 
of each ACG category in the populations as well as the associated cost percentages of 
each ACG in the total cost of hospital C were listed in Table 3.19 according to years.  
Compared with distributions of relative risk in 2010 and 2011 in Figure 3.16, the ACG 
categories which existed in both years showed some similarities. The ACG categories of 
the highest expenditure of hospital C in 2010 and 2011 were ACG 1200 and ACG 3800. 
In 2010, No ACG categories showed extremely high relative risk. However, ACG 1732, 
ACG 3800 and ACG 4100, which were only observed in 2011, were the ACGs categories 
of extremely high risk in 2011.  
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Table 3.19 ACGs Relative Risk Distributions of Hospital C by Years 
ACG 
Number 
ACG Description 2010 
Relative 
Risk 
2010 
Population 
% 
2010 
Cost 
% 
2011 
Relative 
Risk 
2011 
Population 
% 
2011 
Cost  
% 
200 Acute Minor, Age 2 to 5 0.152 0.028 0.004 0.414 0.049 0.02 
300 Acute Minor, Age > 5 0.641 7.674 4.915 0.602 7.778 4.679 
400 Acute Major 0.989 17.928 17.739 0.995 19.644 19.545 
500 
Likely to Recur, w/o 
Allergies 
0.651 31.454 20.489 0.625 31.764 19.845 
600 
Likely to Recur, with 
Allergies 
0.411 0.042 0.017 0.398 0.03 0.012 
700 Asthma 1.117 0.212 0.237 0.573 0.243 0.139 
800 Chronic Medical, Unstable 1.496 21.271 31.825 1.49 21.73 32.382 
900 Chronic Medical, Stable 0.893 8.876 7.929 0.982 7.967 7.821 
1000 Chronic Specialty, Stable 0.591 1.215 0.719 0.608 1.101 0.669 
1100 Eye/Dental 0.515 0.346 0.178 0.524 0.772 0.404 
1200 
Chronic Specialty, 
Unstable 
1.773 0.184 0.326 1.222 0.195 0.238 
1300 
Psychosocial, w/o Psych 
Unstable 
0.551 0.297 0.163 0.591 0.262 0.155 
1400 
Psychosocial, with Psych 
Unstable, w/o Psych Stable 
0.781 0.099 0.077 0.835 0.109 0.091 
1600 Preventive/Administrative 1.507 10.112 15.238 1.41 6.361 8.967 
1712 
Pregnancy: 0-1 ADGs, not 
delivered 
0.257 0.035 0.009 0.417 0.055 0.023 
1732 
Pregnancy: 2-3 ADGs, 1+ 
Major ADGs, not delivered 
n/a n/a n/a 3.398 0.012 0.041 
1800 
Acute Minor and Acute 
Major 
n/a n/a n/a 1.643 0.116 0.19 
2100 
Acute Minor and Likely to 
Recur, Age > 5, w/o 
Allergy 
n/a n/a n/a 0.556 0.061 0.034 
2300 
Acute Minor and Chronic 
Medical: Stable 
n/a n/a n/a 2.11 0.079 0.167 
2500 
Acute Minor and 
Psychosocial, w/o Psych 
Unstable 
n/a n/a n/a 0.841 0.006 0.005 
2800 
Acute Minor and Likely to 
Recur 
n/a n/a n/a 1.324 0.17 0.226 
3800 
2-3 Other ADG 
Combinations, Age < 18 
n/a n/a n/a 6.982 0.006 0.042 
3900 
2-3 Other ADG 
Combinations, Males Age 
18 to 34 
n/a n/a n/a 1.011 0.024 0.025 
4000 
2-3 Other ADG 
Combinations, Females 
Age 18 to 34 
n/a n/a n/a 1.931 0.036 0.07 
4100 
2-3 Other ADG 
Combinations, Age > 34 
n/a n/a n/a 3.071 1.356 4.165 
5110 
No Diagnosis or Only 
Unclassified Diagnosis (2 
input files) 
0.605 0.219 0.133 0.558 0.061 0.034 
5312 
Infants: 0-5 ADGs, no 
Major ADGs, normal birth 
weight 
n/a n/a n/a 0.865 0.006 0.005 
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5312 
Infants: 0-5 ADGs, no 
Major ADGs, normal birth 
weight 
0.055 0.007 0 0.568 0.006 0.003 
 
Figure 3.16 Compare Two Years’ ACGs Relative Risk Distributions Hospital C 
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healthcare expenditures in the Chinese healthcare system as the performance of these 
diagnostic-based risk adjustment models was significantly superior to the traditional 
demographic risk adjustment model in expanding healthcare expenditures and the 
performance of the these diagnostic-based risk adjustment models on the Chinese 
healthcare data was similar to the results reported in literature internationally. The ADGs 
and ACGs showed similar distributions in two consecutive years for a particular 
insurance company or a hospital and therefore were able to profile the clinical 
characteristics and health status for analyzing the underlying populations. The total 
number of ADGs per patient was positively associated with the degree of the risk for the 
group of patients and therefore could be used as a proxy to measure the disease burden of 
a population. The distributions of relative risk showed high and low risk ACGs categories 
within in an insurance company or hospital.             
4.1 Demographics 
 Variability existed in the demographics across the patient populations from 
various data sources. Particularly, significant differences in the demographics were 
observed between the patient populations of the insurance companies and hospitals. First, 
in general, the average ages of the patient populations from the insurance companies was 
about 20 years younger than those of the patient populations from the hospitals, except 
for the patient population from insurance company C in 2010. For most of the insurance 
companies and hospitals, the mean ages of the patients were usually slightly less than the 
median age. The age range for the patient populations from all hospitals and all insurance 
companies were similar except for the patients from insurance company B whose age 
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range was smaller than the age range of the other data sources. Second, the percentages 
of seniors in the patient populations from the insurance companies were significantly 
lower than those from the hospitals except for the patient population from the insurance 
company C in 2010. Slightly lower percentages of male patients were also observed in 
most of the patient populations from the insurance companies and hospitals.  
 Moreover, the statistics of the costs between populations of insurance companies 
and hospitals showed differences. The mean and median costs of the populations from 
insurance companies were about 2-5 times and 7-10 times lower, respectively, than those 
for the populations from the hospitals. For the patients from the insurance companies, the 
mean costs were usually 2-5 times the median costs whereas for the patients from the 
hospitals, the mean costs were usually less than 2 times the median costs.  
 For particular datasets from the insurance companies, the patients of insurance 
company C in 2010 showed deviations from the overall trend of the demographics of the 
populations from other insurance companies. With the highest population average age of 
53 years old among all datasets, the seniors accounted for 26.4% of the patient population 
of insurance company C in 2010, which was similar to the percentages of the inpatient 
populations from the hospitals. Compared with other datasets from insurance companies, 
the mean and median costs of patient population from the insurance company C in 2011 
were significantly higher, and they were similar to the mean and median costs of the 
inpatient populations from the hospitals. Other analytical results of the variables from the 
dataset of insurance company C in 2010 also showed deviations from the overview trends 
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of the populations from the insurance companies as well, and they were discussed in the 
subsequent content in detail.  
 For the particular datasets from the hospitals, the ages of the data from hospital B 
showed slight deviation from the age trend of the hospital populations in both years as the 
average and median ages of hospital B were about 10 years younger than the rest of the 
inpatient populations from the hospitals. This observed difference might be related to the 
scale of the cities as hospital A and C were both in the largest cities of their provinces but 
hospital B was located in a medium size city that also belonged to the same province as 
hospital A. In addition, the mean and median costs of the inpatient population from the 
hospital C were lower than those of the other two hospitals (A, B). This could probably 
be explained by the type of hospitals. The hospital C was a secondary hospital whereas 
both hospital A and hospital B were tertiary hospitals. Therefore, the overall morbidity 
burden of hospital C might be less than the other hospitals.  
4.2 Feasibility   
The rate of mismatched diagnoses is measured by the number of unrecognized 
ICD codes from the ACG system over the total number of ICD codes.
25,49
 If an ICD code 
is not valid for a patient, the ACG system will not be able to recognize it. The 
investigation of the unrecognized ICD codes from the ACG system is critical because it 
reflects the feasibility of the local coding system to the ACG system, the patterns of 
physicians’ practices and documenting issues in healthcare management and 
administration.   
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Reid concluded that the reasons for the unrecognized ICD codes from the ACG 
system were: (1) Errors in transcription of claims generated invalid ICD codes; (2) Codes 
were not specific enough to be mapped into a single ADG; (3) the code was not 
commonly used.
25
 Based on the technical reference guide from the ACG system, the 
acceptable mismatched rate of diagnoses is equal or less than 5%.
62
 A low mismatched 
rate in a study suggests that the specificity and quality of the ICD codes in the local 
system are able to support using the ACG system. However, the analysis of the 
mismatched rate of diagnosis does not necessarily reveal how closely the diagnostic code 
represents a patient’s clinical condition. 
In our study, except for the data from Hospital A, the data from all sources and 
years met the 5% mismatched rate of diagnoses which was a requirement for using the 
ACG system. However, the mismatched rate of diagnoses from hospital A was just 
slightly above the 5% threshold. In this study, all diagnoses were recorded in the ICD-10 
format. For the patients of the insurance companies, the ICD-10 codes had a maximum of 
four characters, of which the last character was the digit after the decimal point.  
Insurance company B only documented the ICD-10 codes in a format of three characters 
by omitting the digits or letters after the decimal point. Some of the ICD-10 codes of 
insurance companies A and C were also documented in this format. The general ICD-10-
CM code structure in the United States is that the first three characters specify the 
category of the disease and the rest of the characters, which are after the decimal point, 
designate the etiology, anatomic site, severity or other clinical information.
63
 China 
adopted and has been using the ICD-10 coding system for the diagnostic classification 
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since 2003. The national guidelines and standards in China specify a diagnosis to the 
fourth character of its corresponding ICD-10 code which means to the level of the 
etiology of the condition. The rest of the characters can be modified and specified in the 
local setting according to its policy.
64
 Therefore, for the patient populations from the 
insurance companies, the diagnostic information included the category and the etiology 
of the disease. For the patients of the hospitals, the ICD-10 codes had a maximum of 
eight characters, suggesting more specific diagnostic information was included for the 
patient populations from hospitals than the patient populations for the insurance 
companies. In addition, the five characters after the decimal point suggested the extension 
of the ICD code, which modified the ICD codes for internal documentation and 
management purposes. The modification of this ICD format was customized by the 
vendors of hospital management system to the local settings based on the requirements 
from local health bureaus, the social health insurance bureaus or the hospitals. Therefore, 
these codes may not be standardized across different hospitals. The ACG system was also 
not able to recognize these ICD codes directly extracted from the hospital management 
system. Thus, different formats of the ICD codes from the hospitals were tested by 
removing a character after the decimal point each time from the right side of an ICD code. 
When one character remained after the decimal point of each ICD code, the rate of 
unrecognized ICD codes was about 10%. After removing all characters after the decimal 
point of each ICD code, which also paralleled to the structure of the ICD-10 codes used 
in the insurance companies, the three-character format of the ICD codes achieved the best 
result of the rate of successfully recognized ICD codes from the ACG system and this 
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ICD format for the hospitals was selected as the final ICD format for the ICD codes that 
was used by the ACG system for further analysis.   
The differences in the ICD format, which was the number of the characters in an 
ICD-10 code, were due to the different workflows and focuses between the insurance 
companies and hospitals. An insurance company manages a significantly larger 
population than a single hospital. An insurance company also needs to document the 
utilization of its patients for every visit in detail whereas hospitals only document clinical 
information in detail for the inpatient patients by the clinicians due to the extremely high 
volume of the outpatient visits. In addition, some insurance companies may not be able to 
directly receive the claim data from the hospital electronically and need to document the 
clinical information manually, which also increased the cost of the documentation. 
Therefore, compared with the data from the hospitals of the inpatient populations, the 
potential high cost associated with documenting clinical information for the insurance 
companies resulted in the lower granularity of the diagnoses and their corresponding 
ICD-10 codes for the data from the insurance companies. Without its subdivision, the 
ICD-10 code format, which only contains three characters, may not provide the greatest 
specificity, but it could still serve the administrative purpose as a code. However, it 
would be ideal that ICD codes are filled in as specifically as possible, so that more 
meaningful clinical information is documented for further analysis.                    
4.3 Morbidity Burden 
 Diagnosis-based risk adjustment models, which use diagnostic information to 
measure the morbidity burden of an individual, can be applied to assess the health status 
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and, therefore, the needs of healthcare resources of a population by aggregating the 
morbidity burden of all individuals. In China, the allocation of healthcare resources is 
mainly based on several factors, such as prior expenditures, the available budget for 
healthcare, the utilization category, and the number of patients in a given region.
65
 
 The morbidity burden measured by the number of ADGs per patient indicated that 
the morbidity burden of the insurance population was higher and more complex than that 
of the hospital population. However, the mean cost per patient of the hospital population 
was higher than that of the insurance population. This might suggest higher morbidity 
burden in the hospital population, which was somewhat directly related to the cost of care. 
This phenomenon could be explained by the differences in documenting diagnoses 
between the two populations. For the inpatient population, the discharge record of a 
patient in the hospital information system only recorded the primary diagnosis which was 
the reason of an admission and the total cost under that admission. For the datasets of the 
hospitals in a given year, the patients who were admitted to the same hospital more than 
once would have multiple diagnoses per year. As one diagnosis was usually mapped into 
one of the ADG categories, only patients with multiple admissions in the same hospital of 
a given year likely had multiple numbers of ADGs in the datasets from the hospitals. 
However, the chance for a patient to be admitted into the same hospital multiple times in 
a given year was very low. Therefore, most patients of the hospital population were only 
assigned one ADG. For the datasets of the inpatient population from the hospitals, due to 
the limited information on the comorbidity and other clinical visits of a patient, the  
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number of ADGs per patient mainly reflected the times that a patient was admitted into 
the same hospital in a given year, rather than the overall disease burden of a patient.  
 By contrast, the insurance companies documented their members’ healthcare 
utilization closely for both inpatient and outpatient visits. Thus, patients who had multiple 
outpatient visits for different reasons in a given year would have multiple diagnoses and 
this may result in the assignment of multiple ADGs to the patients. The number of ADGs 
per patient was typically associated with the number of conditions of the patient, and thus 
could be used as a proxy to reflect the disease burden of each individual of the 
populations from the insurance companies.  
4.4 ADGs Distributions 
 ADGs classification method may assign zero, one or multiple ADGs to a patient 
depending on the patient’s clinical profile. The distribution of the ADGs describes the 
morbidity patterns of the population. In this study, the distributions of the ADGs 
exhibited significant differences between the hospital inpatient population and the 
insurance population at the aggregated data sources level. For the insurance population, 
the following ADG categories had more than 10% of the population in both of the two 
years: the ADG 1 (time limited: minor), ADG 2 (time limited: minor-primary infections), 
ADG 7 (likely to recur: discrete), ADG 10 (chronic medical: stable), ADG 26 
(signs/symptoms: minor), ADG 27(signs/symptoms: uncertain), and ADG 31 
(prevention/administrative). These ADGs usually stood for the health conditions with low 
morbidity burden that could be treated in the outpatient setting. In addition, the frequency 
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of ADG 32 (dental) of the insurance population in two years (9% and 11.7%) was 
significant higher than those of the hospital population (0.01% and 0.02%).       
 By contrast, for the hospital population, ADG 11 (chronic medical: unstable) was 
the only ADG that had more than 10% of the population in two consecutive years. In 
addition, for the following ADGs, their frequency percentages in the patients from the 
hospitals were several times of the frequency percentages in the patients from the 
insurance companies in both years; ADG 3 (time limited: major), ADG 9 (likely to recur: 
progressive), ADG 22 (injuries/adverse effects: major), ADG 29 (discretionary), and 
ADG 32 (malignancy), ADG 33, (pregnancy). These ADGs were often related to the 
conditions of high disease burden and required hospitalization. 
  Clearly, differences existed in the inherent disease burden between the insurance 
population and hospital population at the aggregated data level due to the different 
characteristics of the patients. The data from insurance companies included the 
information for both inpatient and outpatient patients whereas the data from the hospitals 
contained information for only inpatient patients. The disease burden of the outpatient 
populations was generally lower than that was of the inpatient populations. It was also 
common that a patient had outpatient visits several times a year without an inpatient visit.  
Thus, the frequency percentages for certain ADG categories, such as the conditions 
related to outpatient service, in patients of the insurance companies were higher than they 
were in the patients of the hospitals whereas higher frequency percentages of certain 
ADG categories, such as conditions related to the inpatient service, were observed in the 
patients from the hospitals. The differences in the frequency percentages of certain ADG 
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categories between the populations of insurance companies and hospitals indicated the 
ADG categories were able to reflect the unique disease burden for populations with 
different clinic needs and utilizations.  
   At each specific insurance company level, small variations of the frequency 
percentages within each ADG category were observed across years and companies. 
However, the general trends in the frequency percentages across most of the ADG 
categories were similar for all insurance companies and years. Moreover, the frequency 
percentage of the ADGs for the patients from a specific insurance company in two 
consecutive years showed similarities. The variations of the distributions of the ADGs 
among different companies and years might be due to differences in the health status, risk 
selections, beneficial coverage of the insurance plans, and management for the 
underwriting populations. In addition, how the insurance companies documented claims 
would also affect the assignment of ADGs to their members. For example, the frequency 
percentage of ADG 31 (prevention/administrative) was observed in a range of 13%-26% 
in the patients of  insurance company A and  insurance company C, however, its 
frequency percentage was less than 1% for the patients of  insurance company B in both 
years. It was suspected that insurance company B documented the clinical visits related to 
prevention/administrative service differently. In addition, for the data of insurance C in 
2010, compared with its data in 2011 and the data from other insurance companies, the 
distributions of the ADGs showed deviations from the general trends. Particularly, Some 
ADGs represented low disease burdens, such ADG 1(time limited: minor) and ADG 2 
(time limited: minor-primary infections) were observed at lower frequency percentages 
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whereas ADGs represented high disease burdens, such as ADG 11 (chronic medical: 
unstable), and ADG 9 (likely to recur: progressive) were observed at higher frequency 
percentages as 30.92% and 9.63% respectively. The frequency percentages of the ADGs 
of high disease burdens in the patients of the insurance company C in 2010 were even 
higher than the observed frequencies of those ADG categories in the aggregated patient 
population from the hospitals (ADG 11 12.45%-13.55%,  ADG 9 6.55%-6.61%). By 
contrast, the frequencies of ADG 11 and ADG 9 in the datasets of other insurance 
companies were observed in the ranges of 2.29%-5.17 % and 0.09%-0.97% respectively.  
In addition, the frequency percentages of ADG 10 (chronic medical: stable) in the year 
2010, and ADG 27 (signs/symptoms: uncertain) in both years of insurance company C 
were the highest among the data from insurance companies and hospitals. We suspected 
the underwriting population of the insurance company C in 2010 consisted of a 
significant part of inpatient patients or its plan was mainly focused on the inpatient 
hospital care with chronic medical conditions.  
 At each specific hospital level, similar to the insurance companies, small 
variations of the frequency percentages within each ADG category were observed across 
hospitals and years. However, the general trends of the distribution of the ADG 
categories were similar for all hospitals in both years. ADG 17 (chronic specialty: 
unstable-ear, nose, throat) was not observed in the patients from the hospitals at all. 
Several ADGs related to psychosocial conditions, (ADG 23, ADG 24, ADG 25), ADG 
5(allergies), and ADG 34 (dental), were observed at limited frequency percentages in the 
patients from the hospitals.  
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 For hospital A, the ADG 2 (time limited: minor-primary infections), ADG 9 
(likely to recur: progressive) and ADG 11 (chronic medical unstable) were observed at 
higher frequencies for both years than those for hospital B and hospital C; ADG 5 
(allergies) was observed only in the year 2011 with limited frequency percentage (0.01%). 
The unique pattern of the ADGs of hospital A could be partially explained by the type of 
hospital. Hospital A is one of the best hospitals in its province. As a result, patients with 
complex or progressive conditions would come to the hospital to seek care. In addition, 
due to the higher reimbursement rate of the inpatient care from the public medical 
insurance, patients with unstable chronic diseases were more likely to be admitted to the 
hospitals for treatment if there were beds available. Therefore, ADG 9 and ADG 11 were 
observed at higher frequency percentages.     
 For hospital B, ADG 21 (injuries/adverse effects: minor), ADG 22 
(injuries/adverse effects: major), and ADG 33 (pregnancy) showed higher frequency 
percentages than they showed for hospital A and hospital C in both years. The hospital B 
(HB) is a first-class tertiary major medical center of a city with a population more than 
two million in northern China.  It is not like hospital A and hospital C that are both 
located in the largest city in their provinces. However, given a reasonable distance, 
hospital B is the best major medical center in its city and among the nearby suburbs and 
villages. Thus, it is reasonable to see that pregnancy and injuries related conditions, to 
which seeking immediate care is often dependent to the distance of a patient’s home to 
the medical center, were observed at higher frequencies for hospital B than they were 
observed for hospital A and hospital C.  
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 For hospital C, significant high frequency percentages (21.6%, 21.9) of ADG 29 
(discretionary) were observed in two consecutive years. In contrast, the ranges in the 
frequency percentages of ADG 29 for hospitals A and B were between 4.6%-7.4%. This 
may have indicated concerns with the policy for documenting the diagnosis or the 
mapping mechanism of a diagnosis to the ICD code in the hospital’s information system. 
The frequency percentages of ADG 7 (Likely to Recur: Discrete), ADG 8 (Likely to 
Recur: Discrete- Infections), ADG 31 (prevention/administrative) and ADG 32 
(malignancy) were also higher in the patients of hospital C than the other two hospitals. 
In addition, limited frequency percentages (0.02%, 0.06%) of ADG 33 (pregnancy) were 
observed for the patients in hospital C in two years whereas it was about 6% in patients 
for hospital A and it was about 12% in the patients of hospital B.    
 In summary, using ADGs as an instrument, we were able to observe the patterns 
and differences of the clinical characteristics and the associated disease burdens between 
the population of insurance companies and population of hospitals at the aggregated data 
level.  Differences in the risk selections, health conditions of the underwriting 
populations, and beneficial coverage may contribute to the variations in the distribution 
of the ADGs of the patients across insurance companies in a given year. Differences in 
the type of hospitals, regions, and practice patterns of providers may have resulted in the 
variations of the ADG distributions in the patients across hospitals in the given years. 
However, how well the ADGs truly reflected the health status of the underlying 
population relied heavily on the accuracy of documenting the diagnoses of the patients. In 
this study, without detailed clinical notes, we were not able to assess the accuracy of the 
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diagnoses. Therefore, the accuracy of using ADGs to profile the health conditions of 
populations still remains to be investigated in further research.  
4.5 ACGs Distributions  
 Under the ACG mutual-exclusive classification method, each patient was 
classified into only one of the mutual-exclusive actuarial cells known as the ACG 
categories. By aggregating each patient’s ACG assignment, the distributions of the ACGs 
summarized the underlying population’s morbidities patterns into specific categories 
based on clinical characteristics. Compared with the ACG distributions across all 
insurance companies in a given year, the general trends of the frequency percentages of 
each ACG across all datasets were similar except for the data from insurance company C 
in 2010. Higher percentages of certain ACGs were observed in the patients of insurance 
company C in 2010 such as ACG 0800 (chronic medical, unstable), ACG 0900 (chronic 
medical, stable), ACG 4100, (2-3 other ADG combinations, age > 34) and ACG 4420 (4-
5 Other ADG Combinations, Age > 44, 1+ Major ADGs), ACG 4910 (6-9 Other ADG 
combinations age>34, 0-1 major ADGs). These five groups combined accounted for 
about 43% of the population of insurance company C in 2010, whereas they only 
accounted for less than 8% of the populations in the other datasets. Among the five 
groups, particularly, the two groups (ACG 0800, ACG 0900) related to chronic 
conditions accounted for about 26% of the population of the patients in insurance 
company C in 2010 whereas they only accounted for about 3-6% of the patients in the 
other datasets from the insurance companies in a given year. ACG 4420, which 
accounted for 4.2% of the patients of insurance company C in 2010, was infrequently (< 
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0.9%) observed in the patients of the other datasets from the other insurance companies. 
ACG 4910 was observed at a rate of 4.3% and 1.8% in the patients from insurance 
company C in 2010 and 2011 respectively, but it was also infrequent (<0.4%) in the 
patients from insurance company A and insurance company B. However, some ACGs 
related to acute minor conditions were observed at lower rates in the patients from the 
insurance company C in 2010 in comparison with the datasets from the other insurance 
companies. These groups were ACG 0200 (acute minor, age 2 to 5), and ACG 0300, 
(acute minor, age >5). These differences discussed above suggested that the health status 
of the insured population of insurance company C in 2010 was significantly different 
from the other insured populations of insurance companies in a given year, including the 
population of  insurance company C in 2011. These observed differences in health status 
were directly related to the clinical conditions which may have been associated with the 
unique policy of the plan for the insured population from insurance company C in 2010.   
 Some ACGs were observed only in one year of the two years’ data of an 
insurance company. This may because either a certain disease related to the ACGs was 
not observed in the population in that given year or the policy of the insured populations 
changed in the following year. Some ACGs were not observed in the patients of an 
insurance company at all in two consecutive years. For example, psychosocial conditions 
and conditions related to infants were not observed in the patients of insurance company 
B. However, these conditions were observed in the patients of the other insurance 
companies. We suspected that these conditions were not covered by the policy of 
insurance company B. The observed small variations in a specific ACG category of the 
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populations from the insurance companies suggested that both the differences and the 
changes in clinical profiles of the underlying insured populations existed across time and 
companies. Using the ACGs, we were able to observe the difference in clinical conditions 
and morbidity patterns across different insurance companies and years.     
 Compared with the ACG distributions across all hospitals in a given year, most of 
the observed ACG categories showed similar trends. However, the variation of the 
distributions for the ACGs was higher in the patients of the hospitals than that of the 
patients from the insurance companies. This was because, except for the readmitted 
patients in the same hospital during a given year, typically, each patient only had one 
diagnosis in the datasets that were extracted from the inpatient hospital management 
system. Thus, for most of the patients, the assignment of the ACG to the patient was only 
based on the one diagnosis. The available information might not capture all clinical 
characteristics of the inpatient populations and the observed frequencies of the ACGs 
might fluctuate significantly. In addition, the distribution of the ACGs for the patients 
from the hospitals was concentrated on a few ACG categories that were related to the 
acute and chronic medical conditions and these ACG categories accounted for more than 
50% of the inpatient populations.  
 The frequency percentages of certain ACGs of hospital C deviated from the 
general trend of the observed distributions of the ACGs for the patients from the other 
hospitals. The number of the ACG categories for the patients from hospital C was less 
than that of hospital A or hospital B. Some ACG categories, such as ACG 100 (acute 
minor, age 1), ACG 1711 (pregnancy: 0-1 ADGs, delivered), which were frequently 
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observed in the patients from hospital A and hospital B, were absent in the patients of 
hospital C. Some ACG categories that were absent in the patients of hospital C were also 
rarely observed in the patients of  hospital A and  hospital B, such as ACG 1721 
(pregnancy: 2-3 ADGs, no major ADGs, delivered), ACG 1731 (pregnancy: 2-3 ADGs, 
1+ Major ADGs, delivered), ACG 2000 (acute minor and likely to recur, age 2 to 5), 
ACG 4430 (4-5 other ADG combinations, age >44, 1+major ADGs). In addition, some 
ACG categories in the patients of hospital C exhibited higher frequency percentages than 
they were in hospital A and hospital B. For instance, ACG 500 (likely to recur, w/o 
allergies) accounted about 31% of the patients of hospital C, but it only accounted for 8% 
and 10% of the patients of  hospital A and  hospital B respectively. ACG 1600 
(preventive/administrative) accounted for about 6%-10% of hospital C in two years, but it 
only accounted for about 3% for the patients of both hospital A and hospital B.  
 For hospital B, the percentage of ACG 1712 (pregnancy: 0-1, not delivered) was 
much higher than it was for hospital A or hospital C. The percentage of ACG 100 was 
also significant lower in patients of hospital B in 2011 than 2010.   
 For hospital A, the percentage of ACG 5110 (No Diagnosis or Only Unclassified 
Diagnosis) in the patients was much higher than it was for hospital B or hospital C. This 
indicated concerns about the quality of the diagnoses or how diagnoses were mapped to 
the ICD codes within hospital A’s information management system.  
 Clearly, the patterns of the distributions of the ACGs showed significant 
differences between the patient populations of the insurance companies and the patient 
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populations of hospitals. The total number of the observed unique ACG categories was 
higher in the patient population from insurance companies than it was in the inpatient 
populations from hospitals. This could be explained by the difference in the ability to 
completely capture the clinical characteristics and utilizations of the patients between the 
insurance companies and hospitals. Although the ACGs may not completely reflect the 
overall disease burden of a patient from the hospitals, they can reflect the unique disease 
burdens of the patients that a hospital treated during a certain time frame.  
 Overall, the minor and major acute conditions (ACG 100, ACG 200 ACG 300 
ACG 400) accounted for a significant amount of the patient populations of both the 
insurance companies and the hospitals. Chronic conditions (ACG 800, ACG 900 ACG 
1000) existed at higher percentages in the patient populations of the hospitals than in the 
insurance companies. Patients with high morbidity burdens were observed in the 
populations of insurance companies due to their ability to document the clinical visits of 
each patient. In addition, due to the documentation of the comorbidity, conditions related 
to pregnancy presented more complex clinical profiles in the populations of the insurance 
companies than they did in the populations of the hospitals.  
4.6 Regression                
           Overall, the regression model indicated that the diagnosis-based risk adjustment 
model explained the total healthcare expenditures over a time span of one year much 
better than the traditional demographic model both for the patient populations of the 
insurance companies and populations of the hospitals. Within the diagnosis-based models, 
the ADG model outperformed the demographic model for all datasets and slightly 
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outperformed the ACG model in explaining the variation of the total health expenditures 
for most of datasets. The ACG model outperformed the demographic models for most of 
the datasets as a general trend with two exceptions: the dataset of insurance company C 
in 2010 and the dataset of hospital A in 2011, in which the ACG model performed 
inferiorly to the demographic models. This was because although the ACG model 
performed well, the demographic model unexpectedly performed much better on these 
two datasets than on the other datasets. Besides the datasets of insurance company C in 
2010 and hospital A in 2011, the demographic model also performed well for the data 
from hospital A in 2010 and for the data from hospital B in both 2010 and 2011. In these 
datasets, the performances of the demographic model were close to the ACG models, 
however, in most of the cases, the demographic model explained little variations of the 
total expenditures, such as for the datasets of insurance company A, and B, and hospital 
C over two consecutive years as well as the dataset of  insurance company C in 2011.   
 Unique characteristics exhibited in the dataset of the insurance company that the 
unusual performance of the demographics model was observed. First, for the data of 
insurance company C in 2010, the distributions of ACGs and ADGs were quite different 
from the distributions of the other datasets of the other insurance companies. Specifically, 
the percentage of the chronic conditions was very high in the dataset of insurance 
company C in 2010, which was similar to the observed percentages for the data of the 
inpatient population. Of the other five datasets of the insurance companies, the 
percentages of chronic conditions remained very low. Second, the demographics of the 
dataset of insurance company C in 2010 were also different than the other insurance 
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companies. The average age, 53 years old, of the dataset of the other insurance company 
C in 2010 was much older than the rest of the datasets of the other insurance companies, 
which ranged between 20 to 32 years old. In contrast, the average ages of the inpatient 
populations of the hospitals ranged between 42 to 52 years old. Moreover, the mean cost 
for the population of insurance company C in 2010 was much higher than the other 5 
datasets of insurance companies, which were also similar to the average costs for the 
inpatient populations of the hospitals. Based on the analyses of the distributions of the 
ACGs, ADGs and the demographic information, it was suspected that the dataset of 
insurance company C in 2010 mainly consisted of the utilization of inpatient care. Thus, 
the reason for the high performance of the demographic models on the dataset of 
insurance company C in 2010 might be similar to the explanations of the demographic 
model’s performance of the inpatient populations from hospital A and hospital B, which 
were discussed below.     
     For the patient populations of the hospitals, the demographic model’s 
performances for the datasets of hospital A and hospital B in two consecutive years were 
much higher than they were for the datasets of hospital C. Moreover, the demographic 
model’s performance on the datasets of hospital A and hospital B were even similar to 
the performance of the ACG model, but lower than the ADG model on these datasets. In 
addition, the performances of the demographic model on the datasets of hospital A and 
hospital B were also much higher than they were for all datasets of the insurance 
companies except for the dataset of insurance company C in 2010. Hospital A and 
Hospital B were both first-class tertiary hospitals in the same province and it may face 
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significant amounts of patients with similar clinical characteristics, guidelines for 
documenting the diagnoses, and reimbursement policies, which could be greatly 
explained by the demographic variables. However, with the additional clinical 
information, the explanatory power of the ADG model for the total healthcare 
expenditures still increased significantly.   
  The performances of both the diagnosis-based risk adjustment models and the 
demographic model, which were measured by the values of the adjusted R-squared (R
2
), 
were similar to the performances of these models as reported internationally. The 
observed differences between the performances of the diagnosis-based models and the 
demographic models were also similar to the results reported in literature. For example, 
in a study using a province’s data in Canada, in which the data came from a single source, 
the demographic model, the ADGs model and the ACGs model explained 8.1%, 39.6%, 
and 38%, respectively, of the total cost for the populations of all ages. The researchers 
observed the performances of various risk adjustment models on the datasets of the sub-
populations of different age bands fluctuated around the performances of the models on 
the dataset of the population of all ages.
35
 In a study using a group of physicians in Spain, 
the demographic model, the ADGs model and the ACGs model explained 10%, 46%, and 
38% of the total cost for the populations.
66
  
 The variations in the performances of the models may be due to the characteristics 
of the underlying populations. For the populations from the insurance companies, all 
diagnosis-based models showed similar trends in the performances across all populations. 
The ADG models outperformed the ACGs model across all data sources, which were 
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similar to the results reported in literature internationally. However, the performances of 
the ADG models for the datasets of insurance company A in 2010 and 2011, and 
insurance company C in 2011 were below 30%, which were slightly below the 
performances of the ADG models reported internationally. Most of the ACG models’ 
performances were in the range between 20%-30%, which were slightly below the 
reported results of the explanatory power of the ACG model internationally. Compared 
with the performances of the ACG model reported internationally, the lower 
performances of the ACG model in China suggested that the ACG categories may not 
explain the variability of the total health expenditures of the patient populations in the 
Chinese healthcare system as effectively as it has in other countries. This difference could 
be either due to the classification method of the ACG model, which were developed 
according to the claims data in western countries, did not match precisely with the 
combinations of the clinical characteristics of the patients, the practice patterns of the 
physicians, and healthcare cost structures in the Chinese healthcare system or due to the 
concerns of how accurately the physicians and insurance companies documented the 
patients’ conditions. However, in this study, due to the difficulties in obtaining the other 
data elements, we could not assess the influence of these factors on the results of this 
study. Therefore, the exact reasons for the slightly lower performance of the ACG model 
observed in the Chinese healthcare system than the performances reported in other 
countries remain for further investigation. Overall, the regression models indicated the 
validity of the diagnosis-based risk adjustment models from the ACG system in the 
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Chinese healthcare system and the significant improvement of the diagnosis-based risk 
adjustment model in explaining the total health expenditures.  
4.7 Relative Risk 
 The distributions of the relative risk showed different patterns across the 3 
insurance companies in 2 consecutive years. These patterns showed that the values of 
each ACG risk group, which were the ratios of the average cost of a patient in a particular 
ACG over the population’s average cost in the dataset, varied across insurance companies 
significantly. These variations may relate to the differences in the coverage of the plans, 
utilization management, and disease burden among those insurance companies. The 
relative risk compared the average cost per member of an ACG group to the average cost 
per member in the population of an insurance company in a given year. Therefore, 
patients in the ACG groups of high relative risk values can be viewed as the high cost 
patients in the patient population of a given year. Low cost patients in the population of a 
particular insurance company can be identified as the patients in the ACG groups with the 
relative risk less than one, which indicated this patient’s cost was below the average cost 
per patient in the population. Although the patterns of the ACG relative risk’s 
distributions were different across different insurance companies, the distributions of 
relative risk for most of the ACG groups were similar within each company across two 
years. Most of the high cost patients were identified in the ACG groups related to chronic 
conditions, pregnancy, and patients with multiple numbers of ADGs. The low cost 
patients were identified in the ACG groups related to acute conditions. These two trends 
were observed as expected because of the natures of these conditions with respect to the 
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needs of healthcare resources. For the dataset of insurance company C in 2010, the 
distributions of the relative risk for the ACG groups were fluctuated around one. This 
trend indicated the average costs per patient for most of the ACG groups of insurance 
company C in 2010 were close to the average cost per patient in the population. 
Therefore, the deviation of the total health expenditures to the average cost of this 
population at each patient level was low. This may partially explain the observed high 
explanatory power of the demographic model on the dataset of insurance company C in 
2010. The number of patients in the datasets of insurance company A was the largest 
among all three insurance companies. Therefore, the distributions of ACG groups’ 
relative risk showed the highest granularity.      
 For the hospital populations, the values of the relative risk of the ACG categories 
were generally less than those observed for the insurance populations. This suggested the 
variability of the expenditures of the inpatient populations was less than the expenditures 
of the insurance populations, whose expenditures included both inpatient and outpatient 
care. The average expenditure per patient of the inpatient population was much higher 
than that of the outpatient populations. The inpatient population may also share similar 
expenditure structures that derived from the practice and operation patterns of physicians.  
High cost patients identified in the ACG groups were related to preventative and 
administrative service, certain acute minor or major conditions that were associated with 
chronic medical conditions or were likely to recur, patients with multiple numbers of 
ADGs and patients with pregnancy related ADGs. For hospital C, there were significant 
changes for the ACG categories between two years. Compared with the ACG categories 
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of the patients of the hospital C in 2011, some ACGs categories, such as the ACG 
categories starting from ACG 1732 to ACG 4100, were not observed in the inpatient 
population of hospital C in 2010 at all. In 2010, hospital C still used an old hospital 
information management system that was developed several years ago. In 2011, the 
hospital implemented a new information system. Therefore, the observed difference in 
the ACG categories between the two years might be due to the new hospital information 
management system that mapped the diagnosis to the ICD codes with higher granularity 
and accuracy according to the most recent guidelines and standards. This observation also 
suggested the classification of the ACGs heavily relied on the documenting and mapping 
of the patient’s diagnosis to the ICD code within the hospital information system. The 
patients related to the preventive and administrative category were observed as high cost 
patients in several datasets of the hospital. This may raise concerns on how conditions 
were documented in the hospital’s information system. However, due to the higher 
reimbursement rates of inpatient care than outpatient care from public health insurance, 
patients may seek to be admitted to the hospital for treatment if it is possible, regardless 
of whether the conditions can be managed at the outpatient setting or not. Therefore, it 
may not be surprising to see the patients in the preventive and administrative category as 
high cost users. In summary, the distributions of the ACG categories’ relative risk 
showed the values of the relative risk of each ACG were different across various 
insurance companies and hospitals. The difference may be due to the types of clinical 
care the patients received, such as inpatient or outpatient care, which significantly 
affected the average healthcare expenditure per patient, or due to the differences in 
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coverage of the insurance plans. The trends for the high and low risk groups were as 
expected with their needs of healthcare resources. The risk profiles of the patients for the 
same insurance company or hospital across two consecutive years were similar.              
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